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ABSTRACT 
Several studies suggest that consumption of soy protein has positive effects on preventing 
obesity. Preliminary in vitro studies with β-conglycinin showed significant reduction in lipid 
accumulation and inflammatory parameters compared with glycinin. The objective of this study 
was to compare the effect of low glycinin soymilk (LGS) (48% β-conglycinin) with conventional 
soymilk (S) (28% β-conglycinin) and bovine milk (M) (0% β-conglycinin) on body composition, 
serum lipids, biomarkers of oxidative stress and inflammation and gut microbiota in overweight 
men. A randomized, double-blind study was conducted with 64 overweight men (BMI > 25; 18-
45 years old). Subjects consumed 500 mL of each beverage daily for 3 months. Fasting blood 
samples, fecal samples, dual x ray absorptiometry scans, anthropometrics, lipid profile, plasma 
and serum biomarker analyses were executed at baseline and after 3 months. Glycemic index 
measurements were also performed. Total energy, total fat and total protein content were 
standardized among treatments. LGS and S contained similar levels of total isoflavones. Energy 
intake (p = 0.40), moderate physical activity (p = 0.21) and strenuous physical activity (p = 0.49) 
did not change during the study period. Oxidized low density lipoprotein (LDL) was 
dramatically decreased after LGS consumption (-61%) in comparison to S (-36%, p = 0.0007) 
and M (-12%, p = 0.002). Serum antioxidant capacity increased significantly in LGS (18%, p = 
0.001) and S (28%, p < 0.001) compared with M (-40%). The decrease in plasma interleukin-6 
after 3 months of LGS (-22%, p = 0.025) and S (-26%, p = 0.014) consumption was significantly 
different from M. LGS consumption significantly increased plasma adiponectin (14%) compared 
with S (4%, p = 0.039) and M (-8%, p = 0.036). No effects were detected in BMI (p = 0.721), 
waist-hip ratio (WHR) (p = 0.454), weight (p = 0.836), triglycerides (p = 0.947), total cholesterol 
(p = 0.320), plasma leptin (p = 0.655), fatty acid synthase (FAS) (p = 0.976), tumor necrosis 
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factor alpha (TNFα) (0.61) and C-reactive protein (CRP) (p = 0.959) among treatments. LGS did 
not alter bone mineral density (BMD) or t-scores (p >0.05). Changes in total phyla of 
microorganisms (p = 0.36), Lactobacillus (p = 0.06) and Bacteroides (p = 0.27) were not 
significant among treatments. However, universal microbiota increased after three months with 
all treatments. Bifidobacteria changes among treatments were short to significant (p = 0.06), 
showing a decrease with both soymilks consumption however general Actinobacteria increased 
with S (p = 0.06) and LGS (p = 0.07). Relative abundance of Bacteroidetes increased with 
soymilk consumption (LGS: 30% ± 11, p <0.0001; S: 29% ± 10, p = 0.0001). Relative 
abundance of Firmicutes decreased after three months of LGS (-4% ± 2, p <0.0001) and S (-6% 
± 2, p <0.0001) consumption. Dietary intakes of protein, fat, carbohydrates, dietary fiber, 
calcium, iron, phosphorus, potassium, caffeine, vitamins D, B12, K, and E were not influenced by 
LGS, S or M (p >0.05). However, dietary sodium (p = 0.02) and vitamin C (p = 0.0002) intakes 
were reduced with LGS consumption. LGS, S and M are low glycemic index products (41 ± 7, 
40 ± 10 and 29 ± 6 respectively). In conclusion, 3 months of LGS consumption, which is a low 
glycemic index food, inhibited a modest but significant accumulation of body fat, reduced 
inflammation and oxidative stress, and promoted positive intestinal microbiota composition in 
overweight men. Stronger effects of LGS consumption may be observed in combination of a low 
caloric diet and moderate physical activity.  
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I. INTRODUCTION 
According to Center for Disease Control and Prevention (CDC, 2011) the population of the 
United States is obesogenic, and obesity is one of the most important health epidemic issues. An 
obesogenic environment includes multiple stimuli that increase food intake, physical inactivity 
and non-healthful food consumption. Physical inactivity is one of the major factors increasing 
the percentages of obesity of the country. Several regions in Unite States (US) have more than 
32% of the adult population physically inactive (Figure 1)  
 
 
 
 
 
 
 
 
 
Diabetes Data & Trends-CDC, 2011 (Public domain) 
Figure 1. Age-adjusted estimates of the percentage of physically inactive adults (2008) 
 
High caloric intake is the complementary factor promoting obesity in the American 
population. In 2003, the average energy intake in the US and some European countries exceeded 
3600 kilocalories per person per day, which is significantly higher than the world average (2800 
kcal/person/day) (CDC,2011) (Figure 2). The situation has worsened with the high availability 
and variety of unhealthy, energy-dense foods. Two thirds of the US population is either 
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overweight or obese. Wang et al., (2008) projected 90% of the American adult population will be 
overweight or obese for 2030 if this trend does not change. 
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FAO statistical yearbook, 2004 
(Unrestricted use permission) 
 
 
Figure 2. Map of energy consumption (kcal/person/day) per country in 2001-2003. 
 
Scientists all over the world are trying to find solutions to reduce obesity and obesity-
related conditions as well as ameliorate the economic impact on the US health care system. It’s 
evident, that the simple recommendation to eat less and exercise more has not been adopted by 
many. There is a need for research and development of new strategies that meet the comfort, 
taste and nutritional needs of consumers at a low cost.  
The industry of soy products has been involved in developing innovative strategies to try 
to counteract obesity and its side effects. Whole soy, soy isoflavones, and soy protein and 
peptides have been related to many health benefits, for instance; weight lost, reduced body fat, 
improved lipid profiles (Konig et al., 2008), alleviating menopause symptoms (Williamson-
Highes et al., 2006), preventing osteoporosis (Zhang et al., 2005), managing blood pressure 
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(Altorf-van der Kuil et al., 2010), lowering cardiovascular risk (Richard et al, 2010), and 
reducing inflammation and oxidative stress (Valsecchi et al., 2011), among others. There are also 
studies that contradict such findings, as Balk et al. (2005) that suggested small soy effects on 
lipids did not support the effect of soy on endocrine function, menstrual cycles and bone health.  
The general objective of the present study was to compare the effect of low glycinin 
soymilk on body composition, serum lipids, adipokines, biomarkers of oxidative stress, 
inflammation, glycemic response and gut macrobiota composition with conventional soymilk 
and bovine milk in overweight men. The final aim is to increase knowledge of the benefits of soy 
bioactive compounds and to provide new healthy food alternatives for the overweight and obese 
population. 
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II. LITERATURE REVIEW 
 
1. Obesity and weight management 
Currently, the US Dietary Guidelines for adults (2005) define a BMI of 18.5 kg/m
2
 up to 24.9 
kg/m
2
 as healthy weight, body mass index (BMI) of 25 kg/m
2
 up to 29.9 kg/m
2
 as overweight 
and BMI of 30 kg/m
2
 or greater as obesity. BMI is calculated dividing the weight in kilograms 
by the height in meters squared. According to the CDC, BMI is the most reliable indicator of 
body fat. Two-thirds of Americans have a BMI > 25 (CDC, 2011) and the prevalence of obesity 
differs from region to region due to many demographic and intrinsic factors such as age, race-
ethnicity, gender, socioeconomic status, genetics, among others.  
The prevalence of obesity in different ethnic groups can be observed in Figure 3. The black 
non-Hispanic population has a higher prevalence of obesity than Hispanic and white-non 
Hispanic populations. Socio-economic status has an impact on obesity prevalence as well. High 
obesity prevalence in low income groups may be due to consuming energy-dense foods products 
to cover their caloric needs and these products are usually of low cost (Drewnowski and Specter 
(2004). Baum and Ruhm (2007) reported that age is directly related to increments in weight and 
socio-economic status is inversely related to weight gain. Obesity and its related consequences 
elevate the risk of almost every cause of mortality (Ogden et al., 2007). 
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CDC, 2011 
 
 
Figure 3. Obesity among ethnic groups in US (2006-2008). (Public domain) 
 
White Non-Hispanic Hispanic Black Non-Hispanic 
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 The reasons for this epidemic problem are extensive, environmental, physiological and 
motivational obstacles hamper the efforts in the reduction or maintenance of weight 
(VanWormer et al., 2008). A recent publication of the University of Texas Southwestern 
Medical Center summarized the most popular obesity influencing factors in the last years of 
research (Zinn, 2010). This comprehensive analysis gives special importance to the lack of sleep 
hours, psychosocial stress and gut microbiota composition (Figure 4). According to Zinn (2010), 
several studies agree with an inverse correlation of sleep hour and BMI. People sleeping less 
than 8 h per night increases nocturnal snacking, tiredness to do physical activity, gut ghrelin and 
decrease in leptin levels.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zinn, 2010. (Permission by Wolkers Kluwer Health group) 
 
 
Figure 4. Unconventional hypotheses for the etiology of the obesity epidemic 
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Genetic factors are also associated with obesity and numerous genes have been related 
with body weight, for example, melanocortin 4 receptor, β-adrenergic receptor 2 and 3, 
hormone-sensitive lipase, mitochondrial uncoupling proteins 1, 2 and 3 and FTO (Sabin et al., 
2011). However the genetic influence in obesity cannot be isolated analyzed without a deep 
understanding in the obesogenic environment underlying the genetic predisposition.  
Genetics have been widely blamed for the increment in body fat and weight; however, 
genetics only explains 30-70% of changes in BMI (Loos and Bouchard, 2003) and the activation 
of such genes requires singular conditions. For instance, Jacobson et al. (2009) affirmed that 
FTO gene variants associated with obesity is activated only with physical inactivity. Obesity is a 
multifactorial disease and the current and future efforts to find alternatives of solution must 
define the detailed conditions to better understand this this epidemic health concern.  
2. Soybean  
 Soybean is botanically classified into the Rosaceae order, Leguminosae or Papilloceae 
family, Papilionoidae subfamily, Glycine genus and Glycine max cultivar (Mateos-Aparicio et 
al., 2008). The rich nutrient content of soybean has promoted extensive research projects and has 
increased the diversification of soybean products.  A very detailed description of the total 
macronutrient, minerals, lipids and minerals content of soybean and soymilk is shown in Table 1. 
Other soy based products vary in their nutritional profiles however most of them are 
characterized for the high protein content, and depending of their processing, a high percent of 
dietary fiber. Soybean contains several biologically active compounds such as isoflavones, 
saponins, peptides, and proteins with functional properties (Dia et al., 2008). 
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Table 1. Nutritional content of soybean and soymilk 
Nutrients/100 grams  Units  Mature raw soybean  
Soymilk, light, 
unsweetened, fortified 
Proximate Analysis  
  
 
Water  g 8.54 92.03 
Energy  kcal 446 34 
Energy  kJ 1866 140 
Protein  g 36.49 2.62 
Total lipid (fat)  g 19.94 0.85 
Ash  g 4.87 0.64 
Carbohydrate, by difference  g 30.16 3.85 
Fiber, total dietary  g 9.3 0.6 
Sugars, total  g 7.33 0.41 
Minerals  
  
 
Calcium, Ca  mg 277 123 
Iron, Fe  mg 15.70 0.46 
Magnesium, Mg  mg 280 13 
Phosphorus, P  mg 704 103 
Potassium, K  mg 1797 117 
Sodium, Na  mg 2 63 
Zinc, Zn  mg 4.89 0.10 
Vitamins  
  
 
Vitamin C, total ascorbic acid  mg 6.0 0.0 
Folate, total  mcg 375 7 
Vitamin B-12  mcg 0.00 0.23 
Vitamin A, IU  IU 22 206 
Vitamin D  IU 0 41 
Lipids  
  
 
Fatty acids, total saturated  g 2.884 0.078 
Fatty acids, total monounsaturated  g 4.404 0.263 
Fatty acids, total polyunsaturated  g 11.255 0.558 
Cholesterol  mg 0 0 
USDA, 2010 (Public domain) 
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2.1. Soy proteins 
Whole soy contains a significant amount of total protein which varies depending on the 
variety but is usually around 40% of its total chemical composition. Soy proteins are consider of 
very high quality by its amino acid composition and has been associated with multiple health 
benefit. The Food and Drug Administration (FDA) published a recommendation to include 25 g 
of soy protein per day in a diet low in saturated fat and cholesterol may be helpful to improve 
lipid profile. Soy protein is constituted by 90% storage globulins, with glycinin (11S) and β-
conglycinin (7S) proteins as the major storage proteins in soy (Ferreira et al., 2011).  
2.2. β-conglycinin 
The basic β-conglycinin molecule contains subunits of 27 kD and 16 kD chains linked by 
disulfide bonding acting as biotic and abiotic stress protectors in the soybean plants (Shutov et 
al., 2010). β-conglycinin is around 30% of the total protein profile in soybean, and glycinin is 
usually present in higher amount than β-conglycinin  (Mo et al., 2011). β-conglycinin is 
relatively stable molecule. A complex study developed by Hou and Chang (2004) determined 
that β-conglycinin did not present significant changes in all structural characteristics after 18 
months under three conditions: mild adverse (57% RH/20°C), cold (4°C) and uncontrolled 
environmental conditions.  
The consumption of β-conglycinin has been investigated for its nutraceutical potential in 
different obesity-related diseases in vivo and in vitro studies. Soy β-conglycinin have been 
related with decreases in very low density lipoprotein (VLDL) and triglycerides, increments in 
adiponectin (Tachibana et al, 2010), inhibition of fatty acid synthase (FAS) (Martinez-
Villaluenga et al., 2010), reduction of cholesterol (Lovati et al., 2000), reduction of fat 
accumulation and inflammation (Martinez-Villaluenga et al., 2009), inhibition of leukemia cells 
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growth (Wang et al., 2008), prevention of hypertension (Yang et al., 2004),  prevention of 
hyperglycemia, hyperinsulinemia and hyperglycemia (Moriyama et al., 2004), maintenance of 
body fat ratio (Baba et al, 2004), and prevention of obesity (Kohno et al., 2006) among others. 
3. Adipose tissue, inflammation and oxidative stress. 
Adipose tissue is not a fat storage system exclusively. It also secretes hormones of high 
importance in regulation and metabolism (Baudrand et al., 2010). Obesity causes increases in the 
number and size of adipocytes and promotes inflammation due to the presence and accumulation 
of macrophages. These macrophages activate and secrete inflammatory cytokines such as 
Interleukin-6 and TNFα (Tesauro et al., 2011).  
Adipose tissue is located in visceral and subcutaneous depots and obesity accelerates its 
accumulation in these specific depots, throughout the body and other organs such as the heart, 
the kidneys and blood vessels. This expansion of adipose tissue is accompanied by adipokine 
secretion affecting organ functions and systemic metabolism (Ouchi et al., 2011). A detailed list 
of adipokines secreted by adipose tissue is shown in Table 2.   
Obesity is also defined as a low-grade chronic systemic inflammation state worsened by 
physical inactivity and excessive high energy intake. This inflammatory state is related to the 
development of many chronic diseases. Examples of the variety of obesity consequences in 
human health are shown in Figure 5. The obesity-related chronic systemic inflammation is 
usually accompanied by marked physical inactivity. Inflammatory responses are also associated 
with atherosclerosis, neurodegenerative diseases, type 2 diabetes, insulin resistance, and cancer 
(Handschin and Spiegelman, 2008). 
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Table 2. Sources and functions of key adipokines 
 
 
 
Ouchi et al., 2011. (Permission by Elsevier group) 
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Handschin and Spiegelman, 2008. (Permission by Nature publishing group) 
 
 
Figure 5. Consequences of obesity and inflammatory 
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Inflammatory predictors of type 2 diabetes and cardiovascular disease in adults such as 
C-reactive protein (CRP), interleukin-6 and biomarkers of oxidative stress such as oxidized-LDL 
have been under investigation however the influence of different variables on these parameters 
remain partially unclear. Extreme and middle obesity stages have been recently related with high 
oxidative stress and inflammation (Norris et al., 2011).  Correlations between increments in BMI 
and oxidative stress have been reported (Tunc et al., 2010). According to Mellissas et al. (2006) 
oxidative stress may be a key element in obesity pathogenesis. Circulatory levels of oxidized 
LDL are higher in obese individuals than normal and directly correlate with adiposity; however, 
it’s independent of body fat composition. This phenomenon may be the result of the maturity 
acceleration of macrophages promoted by oxidized-LDL (Kelly et al., 2010).  
In an effort to define the adipokine profile of obese and normal individuals, many 
researchers have quantified levels of adiponectin, leptin, IL-6, tumor necrosis alpha (TNFα); 
however the results are still variable. According to Kuo and Helpern (2011) interleukin-6 directly 
correlates with BMI in women, but adiponectin and TNFα is not affected by obesity. 
Leptin and adiponectin are adipocyte-derived hormones that respond to adiposity increments, 
subcutaneous and visceral respectively. Leptin (16k-Da) and adiponectin (30 kD) increase fatty 
acid oxidation and decrease triglycerides (Dyck, 2009). Leptin is a regulator of food intake and 
energy storage dynamic and adiponectin, which is almost exclusively produced by adipose 
tissue, exerts for its strong anti-inflammatory, antiatherogenic, and insulin-sensitizing effect 
(Ouchi and Walsh, 2006).  A complete list of cytokines secreted by adipocytes and/or 
macrophages in human adipose tissue is shown in Figure 6. 
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Based on: Wang and Nakayama, 2010 
 
Figure 6. Cytokines from human tissue 
 
4. Gut microbiota composition 
4.1. Intestinal microbiota composition and obesity 
The human gut is a complex consortium of microorganisms called microbiota whose 
quantification and characterization is not absolutely defined. It is believe that collectively, the 
genome of the gut microbiota contain 100 times more genes than the human genome (Cani and 
Delzene, 2007). One of the essential roles of intestinal microbiota is the metabolism of dietary 
components (Atkinson et al. 2005). According to Serino et al. (2009), variations in nutrient 
intake produce changes in intestinal microbiota and metabolic processes, unbalancing the gram-
positive – gram-negative ratio as well as changes in biomarkers of inflammation. It has been 
recognized that gut microbiota may play an important role in human health due to the fact that 
gut microbiota is different among obese and normal individuals. These advances in science 
motivate to study its different changes to consider a potential gut microbiota manipulation in pro 
of humanity. According to Cani and Delzene (2007), gut microbiota change metabolism by three 
mechanisms: a) gut microbiota increases the capacity to harvest energy from the diet, b) gut 
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microbiota controls triacylglycerol fate and c) gut microbiota modulates the increment in plasma 
lipopolysaccharide levels. Similar theories but not exactly the same was proposed by Tsukumo et 
al. (2009). In this study the researchers explained the link of gut microbiota and obesity through 
three mechanisms (Figure 7); a) microbiota increases energy extraction from indigestible dietary 
polysaccharides, b) microbiota modulates plasma lipopolysaccharides which increases 
inflammation, obesity and diabetes, c) induce regulation of the host genes that modulate how 
energy is expended and stored. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tsukumo et al., 2009 (Permission by Creative Commons) 
Figure 7. Schematic view of the possible mechanism linking gut flora to obesity 
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4.2. Microbiota changes and weight reduction 
Recent findings have tried to explain the relationship between human microbiota, obesity 
and obesity-associated diseases. Backhed et al. (2004) concluded that mice gut microbiota as a 
whole promotes adiposity by the increment in energy harvest from diet and fat storage in adipose 
tissue and liver. Ley (2010) found an association between genetic obesity and altered gut 
microbiota composition which can impact host metabolism, produce effects in inflammation, 
insulin resistance and deposition of energy in fat stores. Others authors believe that the diet is the 
modifying factor in gut microbiota composition (Turnbaug et al., 2008; Nadal et al., 2009). 
 Obesity also has an effect at the phyla level in the microbiota, reducing bacterial 
diversity due to abnormal energy input and altering metabolic pathways as well (Turnbaugh et 
al., 2009). Other specific studies have underlined the impact of calorie restriction and physical 
activity on gut microbiota during weight loss. This study also determined that weight loss is 
associated with an increase in Bacteroidetes and Lactobacillus and to a decrease in Clostridium 
and Bifidobacteria (Santacruz et al., 2009). In the other hand, western diet has been related with 
the increase in Firmicutes and decrease of relative abundance of Bacteroidetes (Turnbaugh et al., 
2008). In addition, high fat diets have also been analyzed and according to Amar et al. (2008) 
high fat intake is directly related with plasma lipopolisaccaride (LPS) levels in men which 
normally come from gram-negative bacteria. LPS is known as the new inflammatory factor from 
microbiota increasing obesity and insulin resistance. 
Type 2 diabetes is also related with different microbiota composition, diabetic subject’s 
microbiota contain less Firmucites and more Bacteroidetes and Proteobacteria than non-diabetic 
subjects, being Bacteroides-Prevotella higher in non-diabetic and Clostridia and C. coccoides-
E.rectale higher in diabetics  (Larsen et al., 2010). In a separate investigation developed by Wu 
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et al. (2010) it was clarified that microbial diversity is not associated with diabetes but rather 
microbiota composition. They also determined that diabetic subjects presented lower proportion 
of Bacteroides vulgatus and Bifidobacteria than non-diabetic subjects.  
The clearest agreement among many studies is that obese microbiota is characterized for 
low abundance of Bacteroidetes and a high abundance of Firmicutes. According to the findings 
that obesity affect gut microbiota diversity, an intentional manipulation of the gut microbiota 
community may be a potential therapeutic option for the overweight and obese population (Ley 
et al., 2005). All these advances have partially clarified some relationships between obesity and 
the intestinal microflora, however deeper analyses about microbial adaptation and mutualistic 
community assembly with different diets and in different environments are still needed.  
5. Glycemic index and glycemic response 
Obesity and diabetes are two health concerns that often have overlapping incidence. In 
Figure 8 we can graphically differentiate how many of the obese population also have type 2 
diabetes. In this regard, governmental institutions and the food industry have tried to educate to 
the consumer about the content and properties of food products to make smart choices to reduce 
health risks. Glycemic index (GI) is a tool used to classify foods based on the glycemic response 
and is defined as the glucose response area under the curve after 25-50 g of carbohydrate 
consumption. Low glycemic index products may be tested with lower than 50 g carbohydrate 
consumption (Cocate et al., 2011). The Food and Agriculture Organization (FAO) of the World 
Health Organization (WHO) defined the GI in 1998 as the incremental area under the blood 
glucose response curve of a 50 g carbohydrate of food expressed as a percent of the response to 
50 g of carbohydrate from a standard food in same subject (FAO/WHO, 1998). The American 
Diabetes Association classifies as low GI, medium GI and high GI foods with GI’s of 55 or less, 
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56-69 and more than 70 respectively. Several studies have claimed successful maintenance of 
glucose concentrations with the consumption of low GI foods (Stevenson et al., 2005). High GI 
produces a higher postprandial blood glucose response after 2 h of consumption (Foster-Powell 
et al., 2002). This reaction may be due to slower digestion and absorption rates (Brand-Miller et 
al., 2004). Isken et al., 2010) reported that only long term (not short term) consumption of high 
GI foods results in obesity, insulin resistance and metabolic complications. Contradictory, 
Cocate et al. (2011) failed to confirm different glycemic responses between low and high GI 
foods. The determination of GI is still controversial due the variable responses observed in the 
same type of products. Measurement methods, food ingredients and food processing conditions 
must be take into consideration when compared GIs. For instance, larger degrees of processing 
yield higher GI responses (Fernandes et al., 2005). Ripeness and storage time have a marked 
influence in glycemic index measurements (American Diabetes Association, 2011). The 
methodology used also may influence the variances in results, for instance, capillary blood 
samples are more reliable than venous blood samples to determine GI (Wolever et al., 2003).  
Low GI diets have shown improvements in glycemic control, reduction in serum lipids, 
cardiovascular risk and diabetes risk (Jenkins et al., 2002). The effects that a low GI diet has on 
obese individuals are also debated. Low GI diets have been related to increments in satiety 
(Ludwig, 2000).  The consumption of low GI products in order to prevent the development of 
diabetes or other obesity-related issues may be achieved by replacing a) energy from 
carbohydrates with energy from proteins, b) energy from carbohydrates with energy from fat, or 
c) replace high GI with low GI foods (Brand-Miller, 2004). International tables of GI of foods 
have been published and used by the scientific community as instruments to evaluate the 
relationship between glycemic index and human health; however new reliable information is 
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needed for update of such tables. Glycemic loads are also related to lower risk of cardiovascular 
disease and are calculated multiplying the GI of a food by the available carbohydrate present in 
that food divided by 100 (Lacombe and Ganji, 2010) .  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. Diabetes map 2007.   B.   Diabetes and obesity incidence 2007. Blues are counties in the top 2 quintiles of both 
diabetes and obesity. Blacks are in the bottom 2 quintiles of both diabetes and obesity. CDC, 2011 (Public 
domain) 
 
Figure 8. Obesity and diabetes prevalence in US adult population in 2007. 
 
A. Diabetes 
B. Obesity and diabetes 
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III. RESEARCH SIGNIFICANCE 
Heart disease and stroke, in association with obesity, will be the leading causes of death 
in the world for 2020. In addition, obesity is one of the most important contributors of premature 
mortality and is associated with several metabolic disorders resulting in high levels of serum 
lipids and abnormalities in biomarkers of inflammation, oxidative stress which in turn are also 
associated with adiposity and weight gain. It is also important to keep in mind that oxidized LDL 
(ox-LDL) plays a key role in the development of atherosclerosis and cardiovascular disease and 
contribute to the development of obesity-related diseases.  Additionally, elevated levels of 
interleukins and C-reactive proteins are result of chronic inflammation. An approach to mitigate 
the incidence of obesity and metabolic disorders should include exercise and replacing high 
energy foods with healthy foods containing bioactive compounds with positive impacts in gut 
bacteria composition, glycemic response, lipid metabolism, inflammation and oxidative stress. 
Soybean [Glycine max (L.) Merr.] is a rich source of proteins and bioactive compounds which 
have been related to the prevention fat accumulation and cardiovascular diseases. The ratio of β-
conglycinin and glycinin present in soy may produce different positive effects in human health. 
Thus, β-conglycinin has received particular attention as potential agent to improve health of 
overweight individuals. The effect of consuming whole soy foods made from low glycinin 
soybean enriched in β-conglycinins is unknown. Recent studies have tried to explain the role of 
soy proteins in health factors such as bone density, glycemic response and intestinal microbiota; 
however the results are still inconclusive. The complex mixture of protein and isoflavones 
present in soy have been studied, showing positive effects in bone health with consumption of 
soy isoflavones and soy proteins however other studies contradict such results. Nutritional intake 
and physical activity changes were of important consideration in the present analysis, in order to 
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determine all possible influencing factors. Also, gut microbiota changes were studied due to the 
unclear influence of the consumption of soy-based products in gastrointestinal function and 
health. Given this background, it was hypothesized that the consumption of low glycinin soybean 
could be beneficial for oxidative stress, inflammation, gut microbiota and body composition in 
overweight individuals.  
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IV. HYPOTHESIS AND OBJECTIVES 
1. Hypothesis 
Low glycinin soymilk modulates body fat accumulation, serum lipids and biomarkers of 
oxidative stress and inflammation and benefits microbiota composition in overweight 
men.  
2. Main objective 
To compare the effect of a low glycinin soymilk in body fat accumulation, serum lipids, 
biomarkers of oxidative stress, inflammation, glycemic response and gut microbiota with 
conventional soymilk and bovine milk in overweight men. 
3.  Specific objectives 
 Compare the changes in body fat accumulation and anthropometric parameters in 
overweight men after three months of consumption of low glycinin soymilk, conventional 
soymilk and bovine milk. 
 Determine the effect of low glycinin soymilk on bone mineral density and nutrient intake 
in overweight men. 
 Analyze serum lipids, antioxidant capacity and biomarkers of inflammation and oxidative 
stress after three months of consumption of low glycinin soymilk, conventional soymilk 
and bovine milk. 
 Compare the changes in gut microbiota composition in overweight men after three 
months of consumption of low glycinin soymilk, conventional soymilk and bovine milk. 
 Determine the glycemic response of two soy milks as compared to bovine milk. 
 
 
23 
 
V. MATERIALS AND METHODS 
1. Subjects 
Participants included otherwise healthy overweight men, age18-45 years with body mass 
index (BMI) (25-44) , non-vegetarian, non-athletes, and non-smokers, recruited voluntarily from 
the campus of the University of Illinois, Urbana-Champaign using fliers. They participated in an 
initial orientation meeting on the procedures of the study and signed a consent form.  
Age, BMI, weight, waist-hip ratio, body fat composition were measured at baseline to 
organize subject whiting groups using a stratified randomization. There were not statistical 
differences among groups in any baseline anthropometric characteristics (P > 0.05). Based on 
BMI, these individuals are considered as pre-obese subjects according to the WHO criteria. They 
agreed to maintain their regular diet and physical activity during the study. Subjects were asked 
to avoid consumption of dietary supplements, antibiotics and to inform investigators about any 
new disease condition or new medication. 
2. Soymilk and bovine milk products 
The low glycinin soybean/high β-conglycinin seeds were provided by The Monsanto Co. 
(Saint Louis, MO). The corresponding whole soybean milk powders, including the one from 
traditional soybean seeds were manufactured by Archer Daniels Midland (Decatur, IL). The 
liquid preparation and packaging of the soymilk beverages and bovine’s milk were conducted 
using an Ultra High Temperature procedure (Tetra Pak Co., Danton, TX).  
The process compresses a preheating at 175 °F for 1 second, homogenization at 1500 psi 
and pasteurization at 285°F for 3 seconds. Milk was then cooled at 90°F and packaged in Tetra 
Brik material by Tetra Therm Aceptic System by Tetra Pak (Figure 9). This high thermal process 
allowed a shelf life of the product of 12 months without refrigeration and 24 months under 
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refrigeration temperatures. Final products were condemned for 2 weeks and microbiologically 
analyses were performed by Tetra Pak to ensure safety status of the samples previous to the 
shipping to University of Illinois. 
 
 
 
 
 
 
 
Ingredient mixer tank                              Aseptic holding tank          Tetra Therm Aseptic System 
 Source: (Tetra Pak, Danton TX) 
 
Figure 9. UHT equipment for Tetra Pak milk samples processing 
3. Study design 
The study was a randomized, double-blind trial. It was conducted in accordance with 
good clinical practice guidelines in compliance of the declaration of Helsinki and approval of the 
Institutional Review Board of the University of Illinois at Urbana- Champaign (IRB #09454). 
Eighty one volunteers who met the inclusion criteria were randomly distributed into three groups 
to consume 500 mL per day of low glycinin (high β-conglycinin) soymilk (LGS), conventional 
soymilk (S) or bovine milk (M).  
The originally enrolled participants (n = 81), were staggered from June to December 
2009 and 64 subjects completed the study. The study comprised one week of washout period in 
which subjects were requested to avoid the consumption of any food product containing soy; a 
complete list of food products to avoid was provided. Consumption of any other fluid milk intake 
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was prohibited. The washout period was followed by three months of soymilk or bovine’s milk 
consumption according to the experimental protocol.  
The test products were provided to participants to take home or at work in 250 mL Tetra 
Pak containers that looked exactly the same, with instructions to consume two portions (500 mL) 
per day. Compliance of product consumption was determined monthly by counting the number 
of clipped cardboard codes returned monthly to investigators and by a signed declaration of the 
number of beverage packages consumed.  
4. Body composition and anthropometrics 
4.1 Anthropometric measurements 
Body weight, height, waist and hip circumferences were measured in triplicate at baseline, 1, 
2 and 3 months. Body weight was measured without shoes and wearing medical clothes using an 
electronic scale (Tanita, model BWB-627A), height was measured with a regular stadiometer 
and waist and hip circumference on a horizontal plane with a Nontretch anthropometric tape. The 
waist circumference was measured at a level midway between the lowest rib and the iliac crest 
and the hip circumference at the level of the great trochanter. All anthropometrics were measured 
by the same person three times during each meeting.  
4.2. Body fat and lean composition 
Subjects changed into medical clothing or wore light-weight clothing and removed all 
jewelry and other clothing except underwear. Dual Energy X-ray Absorptiometry (DXA) scan of 
total body fat, left arm, right arm, left leg, right leg and trunk fat and lean composition were 
measured at baseline and after three months of milk consumption. All DXA scans were 
performed by an Illinois state licensed X-ray technologist and analyzed by the same investigator 
trained in scan analysis by Hologic. Total body scan time lasted approximately 5 min. Scan 
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acquisition of total body was performed with a single beam whole-body scanner (Illinois: 
Holistic 4500A, software version 11.1.3). Individual scans were analyzed by the same person 
according to standard manufacturer’s procedure. The suprailiac trunk region (trunk percent fat) 
was defined superiorly as one-third the distance from the superior aspect of the iliac crest to the 
knee joint, from the superior iliac crests and inferiorly as a horizontal line at the level of the 
superior iliac crest (Figure 10). Each scan was reviewed for quality control by one of the 
investigators and was judged technically satisfactory if the external calibration step phantom and 
the skeletal outline of the subject lay within the scan region and without significant movement 
artifact. Any subject with more of 300 pounds of weight was recruited following the DXA scan 
restriction. 
 
Figure 10. DXA scan zones 
4.3. Bone mineral density 
Bone mineral density (BMD) was also measured with a Dual Energy X-ray Absorptiometer 
(DXA) scans (Illinois: Holistic 4500A, software version 11.1.3) at baseline and at the end of the 
study.  The technique is based on the relative tissue absorbance of X-radiation at two energy 
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levels and is very stable, and DXA estimated bone mineral content (BMC) and bone mineral 
density (BMD). This estimate is made by comparing the energy levels passed through the men 
with the energy levels passed through calibrated samples of bone, soft tissue and air. Quality 
control for DXA measures was verified by scanning a Hologic calibration phantom of known 
mineral content before testing. Using the tissue calibration bar, energy levels were determined 
for equivalent lean and fat tissues. With this calibration, the fat mass, lean mass and percent fat 
were estimated.  Individual scans were analyzed by the same person according to standard 
manufacturer’s procedures.  
Precision for DXA bone mineral density measures is 1-1.5% CV% calculated from duplicate 
scans of young adults. BMD changes were measured as an increase or decrease in g/cm
2
. 
Comparison of BMD T-scores after three months was also conducted. The BMD-T score was 
calculated from the BMD of the patient (BMDp) and the mean of a healthy adult (BMDµ) and 
standard deviation (BMDσ) of healthy young adult of the same age and ethnicity using the 
following formula: BMD-T-scores = (BMDp) - (BMDµ) / (BMDσ). 
5. Dietary and physical activity assessment 
5.1. Five-day diet record 
A five-day dietary record was used to assess monthly nutrient intake during the period of 
the study. Participants were trained on portion size and on proper management of personal 
dietary records. Serving sizes were reported according to USDA guidelines for the US 
population (USDA, 1996). Consumption data were filled out at home by the subjects and 
received monthly upon an interview with investigators. Dietary records were analyzed with the 
Food Processor SQL, Nutrition Analysis and Fitness Software (version 10.5.0, ESHA Research) 
and were revised by a second investigator. 
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5.2. Seven-day physical activity recall (SDPAR) 
A seven-day physical activity recall (SDPAR) was conducted by trained interviewers 
every month. Subjects were asked to list the frequency, length and intensity of physical activity 
seven days prior to the interview.  Data collected provided number of daily hours of physical 
activity with moderate, mild and strenuous intensity as well as the sleep hours. Moderate 
physical activity included fast walking, tennis, easy bicycling, volleyball, softball, easy 
swimming, dancing. Mild physical activity included yoga, easy walking, and bowling. Strenuous 
physical activity included running, jogging, hockey, football, soccer, basketball, karate, vigorous 
swimming, long distance bicycling. Changes in hours per day of mild-moderate and strenuous 
physical activity were analyzed throughout the study. 
6. Lipid profile, adipokines, oxidative stress, inflammation and assessment 
6.1. Blood samples collection 
Fasting blood specimens (12 h) were obtained by venipuncture of the anti-cubital vein at 
baseline, 1, 2 and 3 months of milk consumption. Samples for blood plasma were collected in 
BD vacutainers-K2 EDTA and for serum in BD Vacutainers SST
TM
 (BD Diagnostics, Franklin 
Lakes, NJ). After centrifugation at 3000 g for 15 min at 4 °C, the resulting plasma and serum 
were aliquoted into cryovials and stored at -80 °C until analyses.  
6.2. Serum lipids and fatty acid synthase (FAS) 
Serum lipids were measured in serum samples at baseline and 3 months and the relative 
differences were calculated. Serum total cholesterol was measured with a fluorometric assay 
from Cayman Chemical (Ann Arbor, MI). This assay is based on an enzyme-coupled reaction 
that detect both free cholesterol and cholesteryl ester which are hydrolyzed by cholesterol 
esterase into cholesterol, which is then hydrolyzed by cholesterol oxidase to yield hydrogen 
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peroxidase and ketone products. Hydrogen peroxidase is detected using ADHP (10-acetyl-3,7-
dyhydroxyphenoxazinw). Fluorescence was read with 565-580 nm of excitation and 585-595 nm 
of emission wavelength. Cholesterol concentrations were documented as µM of cholesterol using 
the formula Cholesterol (µM) = [(sample adjusted fluorescence – y-intercept)/slope]*sample 
dilution*0.001. The assay had an intra-assay and inter-assay coefficient of variation of 6.4% and 
3.4% respectively.  
Serum triglycerides were measured with a Triglyceride assay kit from Cayman Chemical 
(Ann Arbor, MI). This tool was sensitive to detect serum or plasma triglycerides and uses an 
enzymatic hydrolysis of the triglycerides by lipase to glycerol and free fatty acids. The glycerol 
released is subsequently measured by a coupled enzymatic reaction. The glycerol formed is 
phosphorylated to glycerol-3-phosphate in a reaction catalyzed by glycerol kinase. Then the 
glycerol-3-phospate is oxidized by glycerol phosphate oxidase producing dihydroxyacetone 
phosphate and hydrogen peroxide. Subsequent reaction produce a brilliant purple detected and 
quantified by spectrophotometry at 550 nm. Triglycerides concentrations were calculated as 
mg/dL of human serum = [corrected absorbance - y-intercept)/slope]. The assay had an intra-
assay and inter-assay coefficient of variation of 1.34% and 3.17% respectively. 
Plasma fatty acid synthase (FAS) was analyzed using a FAS-detection
TM
 human ELISA 
from FASgen
TM
 (Baltimore MD) following the standard manufacturer procedures. Briefly, this 
double sandwich ELISA assay is used to detect soluble FAS in human serum. FAS antigen and 
Biotinylated FAS detection antibody were used. Horseradish peroxidase-labeled Streptavidin 
was used for detection and a FAS standard curved for quantification (Figure 11). Two different 
quality control standards were used and the failure of one of them produced the repetition of the 
entire plate. Results were obtained in ng/mL of serum and absorbance was read at 450 nm     
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Plates were read in a multimode microplate reader Biotek Synergy 2 and the concentration 
calculations with the software Biotek Gen5
TM
 (Winooski, VT). 
 
 
 
 
 
Curve Formula A B R² 
Y=A*X+B 0.0416 -0.00951 0.991 
 
Figure 11. Example of fatty acid synthase (FAS) standard curve 
 
 
6.3. Plasma adiponectin and leptin 
Plasma adiponectin and leptin were determined by a human adiponectin enzyme-linked 
immunosorbent assay (ELISA) and human leptin ELISA, both from Millipore (St Charles, MO). 
Plates were read in a multimode microplate reader Biotek Synergy 2 and the calculations of 
concentrations were conducted with the software Biotek Gen5
TM
 (Winooski, VT). Adiponectin 
sandwich ELISA used a monoclonal anti-human adiponectin antibodies and a secondary 
biotinylated monoclonal anti-human antibody. Quantification of the immobilized antibody-
enzyme conjugates was done by measurement of horseradish peroxidase activity under the 
presence of 3,3’5,5’-tetramethylbenzdine. Adiponectin absorbance was read at 450 nm and 590 
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nm and compared against a standard curve (Figure 12). The assay had an intra-assay and inter-
assay coefficient of variation of 1.8% and 6.2% respectively.  Leptin assay was performed under 
the same principle but using a polyclonal rabbit anti-human antibody and secondary biotinylated 
monoclonal antibody.  Leptin absorbance was read at 450 nm and 590 nm and presented an intra-
assay and inter-assay coefficient of variation of 1.9% and 1.3% respectively.   
 
 
 
 
 
 
 
 
 
Curve Formula A B C D E R² 
Y = (A-D)/(1+(X/C)^B)^E + D 0.0118 1.18 1.54E+04 1.16 211 1 
 
Figure 12. Example of plasma adiponectin standard curves 
 
6.4. Serum oxidized-LDL 
Serum oxidized-LDL (ox-LDL) was measured using enzyme-linked immunosorbent 
assay ELISA from Cayman Chemical (Ann Arbor, MI). To determine the levels of ox-LDL a 
double-antibody sandwich technique was used. The 96 microwell plate was coated with human 
ox-LDL-β2GPI antibody. The bound β2GP was detected using horseradish peroxidase (HRP)-
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labeled monoclonal antibody. The concentration of ox-LDL-β2GPI was determined measuring 
the enzymatic activity of the HRP using tetramethylbenzidine (TMB). The concentration of 
plasma oxi-LDL was determined by spectrophotometry (450 nm) equivalent to the amount of 
bound conjugate compared against the standard curve (Figure 13). The assay had an intra-assay 
and inter-assay coefficient of variation of 1.34% and 3.17% respectively.   
 
 
 
 
 
 
 
 
Curve Formula A B C R² 
Y=C*X^2+B*X+A 0.0607 2.51 -0.0903 0.995 
 
Figure 13. Example of oxidized-LDL standard curve 
 
 
6.5. Serum antioxidant capacity  
Serum anti-oxidant capacity biomarkers of inflammation and oxidative stress were 
measured only at baseline and at the end of the study. Serum antioxidant capacity was 
determined using the Oxygen Radical Absorbance Capacity (ORAC) procedure described by 
Prior et al. (2003). Briefly, aliquots of 20 μL sample, Trolox standard dissolved in 75 mM 
phosphate buffer pH 7.4 or 75 mM phosphate buffer pH 7.4 blank were added to a 96-well black 
walled plate.  This was followed by the addition of 120 μL 17 nM fluorescein. The plate was 
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then incubated for 15 min at 37 ˚C and then 60 μL of 153 mM AAPH were added.  The plates 
were read in a fluorescent plate reader, FLx800tbi (Bio-Tek, Winooski, VT), at 37 ˚C, sensitivity 
60, read every 2 min for 120 min with excitation 485 and emission 582 nm.  Results were 
expressed as mmol Trolox equivalents as compared with the standard curve (Figure 14). Plates 
were read in a multimode microplate reader Biotek Synergy 2 and the calculations of 
concentrations were conducted with the software Biotek Gen5
TM
 (Winooski, VT). 
 
Figure 14. Example of Trolox equivalents standard curve 
 
6.6. Plasma interleukin-6, C-reactive protein and tumor necrosis factor alpha  
Plasma interleukin-6 (IL-6) was measured with an interleukin-6 (human) immunometric 
assay EIAs and changes in plasma tumor necrosis factor alpha (TNFα) were determined by an 
ACE
TM
 immunometric assay EIAs, both from Cayman Chemical (Ann Arbor, MI). The 
inmunometric assay is based in a double-antibody sandwich technique. This techniques uses an 
acetylcholinesterase:fab conjugate (AChE) to bind IL-6 molecules. The sandwich of antibodies 
were immobilized with Ellman’s reagent and washed to determine the concentration by 
34 
 
Curve
<Plate Layout Settings>
B
la
n
k
 4
0
5
-50 0 50 100 150 200 250 300
-0.500
0.000
0.500
1.000
1.500
2.000
2.500
measuring the enzymatic activity of AChE. The concentration was determined by 
spectrophotometry by comparison of the bound conjugates against a standard curve (Figure 15).  
Inteleukin-6 EIA assay had an intra-assay and inter-assay coefficient of variation of 4.6% 
and 15.6% respectively and the absorbance was read at 405 nm. EIA permits Il-6 measurements 
within the range of 0-250 pg/mL. Changes in plasma C-reactive protein (CRP) was also 
determined by a C-reactive protein (human) ELISA technique from Cayman Chemical (Ann 
Arbor, MI) following the double sandwich ELISA principle. The assay had an intra-assay 
coefficient of variation of 3.0% and the absorbance was read 450 nm. Plates were also read in a 
multimode microplate reader Biotek Synergy 2 and the calculations of concentrations were 
conducted with the software Biotek Gen5
TM
 (Winooski, VT). 
 
 
 
 
 
 
  
 
 
 
 
Figure 15. Example of interleukin-6 standard curve 
 
Curve Formula A B R² 
Y=A*X+B 0.00804 0.0141 0.997 
A
b
s
o
r
b
a
n
c
e 
Interleukin-6 (pg/mL) 
35 
 
7. Fecal microbiota composition quantification 
7.1. Fecal material preparation 
Fecal material collection was deposited by the participants in a commode specimen 
collection system (Fisher Scientific, Hanover Park, IL) and placed in a Styrofoam box and kept 
on ice by participant.  Three fecal samples were collected from three different drop-offs and 
frozen within two hours of defecation at baseline and after 3 months (Figure 16).  Four total 
samples were collected from each separate drop-off into tubes (3-200 mg and 1 -1 g tube; 
Sarstedt 80.734.001 and 80.623.022 respectively).  DNA was isolated from 200 mg of colonic 
contents and purified by QIAmpDNA Stool Kits (Qiagen, Germantown, MD), in combination 
with glass beads beating. The primers used for qPCR are listed in Table 3.  
7.2. General quantification of microbiota using q-PCR 
PCR was performed in Applied Biosystems 7900HT Fast Real-Time PCR l and qPCR 
with reactionSystem (Applied Biosystems). A master mix containing 5 µl of 2Χ Power SYBR 
Green PCR Master mix (Applied Biosystems), bovine serum albumin with a final concentration 
of 1 μg BSA /μL (AEngland Bio Labs, Ipswich, MA), 0.5 µM of each primer and 2 μL of 1:100 
diluted DNA sample was prepared. The PCR conditions were 50 ºC for 2 min, 95 ºC for 10 min, 
followed by 40 cycles of 95 ºC for 15 s, and 60 ºC for 1 min.  A dissociation step was included to 
analyze the melting profile of the amplified products.  
Standard curves (10
1
 to 10
6
 16S rRNA gene copies per reaction) were generated using 
purified 2.1TOPO-TA plasmids (Invitrogen, CA) containing the 16S rRNA gene of 
Lactobacillus rhamnosus (used for Lactobacillus and universal quantitation), Bifidobacterium 
longum, and Bacteroides fragilis.  Results are presented as number of 16S rRNA gene copies per 
g colon contents (dry basis). The accuracy of the methodology used for this kind of studies have 
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been subject of  criticism, however q-PCR have been defined as a powerful technique to study 
the diverse and complex human fecal microbiota matrix (Mariat et al., 2009). 
 
Figure 16. General microbiota analysis diagram 
 
Table 3. Primers used for quantification of Total Bacteria, Bacteroides, Bifidobacterium and 
Lactobacillus 
Target group Primer Sequence (5’-3’) 
Total bacteria Uni331F 
Uin797R 
TCCTACGGGAGGCAGCAGT 
GGACTACCAGGGTATCTATCCTGTT 
Bacteroides AllBac296F  
AllBac2112R  
GAG AGG AAG GTC CCC CAC  
CGC TAC TTG GCT GGT TCA G  
Bifidobacterium  Bif164F 
Bif662R 
GGGTGGTAATGCCGGATG 
CCACCGTTACACCGGGAA 
Lactobacillus LacF 
LacR 
AGCAGTAGGGAATCTTCCA 
CACCGCTACACATGGAG 
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8. Genera identification by pyrosequencying 
8.1. DNA extraction 
Fecal samples were homogenized and 200 mg aseptically suspended in 500 µl RLT 
buffer (Qiagen, Valencia, CA) (with β- mercaptoethanol).  A sterile 5 mm steel bead (Qiagen, 
Valencia, CA) and 500 µl volume of sterile 0.1 mm glass beads (Scientific Industries, Inc., NY, 
USA) were added for complete bacterial lyses in a Qiagen TissueLyser (Qiagen, Valencia, CA), 
run at 30 Hz for 5 min. Samples were centrifuged and 100 µl of 100% ethanol added to a 100 µl 
aliquot of the sample supernatant. This mixture was added to a DNA spin column, and DNA 
recovery protocols were followed as instructed in the Qiagen DNA Stool Kit (Qiagen, Valencia, 
CA) starting at step 5 of the Protocol. DNA was eluted from the column with 50 µl water and 
samples were diluted accordingly to a final nominal concentration of 20 ng/µl.  DNA samples 
were quantified using a Nanodrop spectrophotometer (Nyxor Biotech, Paris, France).   
8.2. Massively parallel bacterial tag encoded EFL amplicon pyrosequencying (bTEFAP) 
Bacterial tag-encoded FLX amplicon pyrosequencing (bTEFAP) was performed using 
Gray28F 5’TTTGATCNTGGCTCAG and Gray519r 5’ GTNTTACNGCGGCKGCTG as 
described in previous studies (Dowd et al., 2008; Callaway et al., 2009; Wolcott et al. 2009; 
Smith et al., 2010). Initial generation of the sequencing library used a one-step PCR with a total 
of 30 cycles, a mixture of Hot Start and HotStar high fidelity taq polymerases, and amplicons 
originating and extending from the 28F for bacterial diversity.  Tag-encoded FLX amplicon 
pyrosequencing analyses utilized Roche 454 FLX instrument with Titanium reagents, titanium 
procedures performed at the Research and Testing Laboratory (Lubbock, TX) based upon RTL 
protocols (Down et al., 2008). 
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8.3. Bacterial diversity  
Following sequencing, all failed sequence reads, low quality sequence ends and tags and 
primers were removed and sequences collections depleted of any non-bacterial ribosome 
sequences and chimeras using B2C2 (Gontcharova 2010) as has been described previously 
(Wolcott et al. 2009; Smith et al., 2010; Ishak et al., 2011; Dowd et al., 2008).To determine the 
identity of bacteria in the remaining sequences, sequences were denoised, assembled into clusters 
and queried using a distributed BLASTn .NET algorithm (Dowd et al., 2005) against a database 
of high quality 16S bacterial sequences derived from NCBI (01-01-11 or current version).  
Database sequences were characterized as high quality based upon similar criteria utilized by 
RDP ver 9 (Cole et al. 2009).  Using a .NET and C# analysis pipeline the resulting BLASTn 
outputs were compiled and validated using taxonomic distance methods, and data reduction 
analysis were performed as described in the standard method (Dowd et al. 2005; Gontcharova et 
al., 2010; Handl et al., 2011; Guerrero et al., 2009; Sen et al., 2009).  
8.4 Bacterial identification 
Based upon the above BLASTn derived sequence identity (percent of total length query 
sequence which aligns with a given database sequence) and using taxonomic distance methods 
the bacteria were classified at the appropriate taxonomic levels based upon the following criteria.  
Sequences with identity scores, to known or well characterized 16S sequences, greater than 97% 
identity (<3% divergence) were resolved at the species level, between 95% and 97% at the genus 
level, between 90% and 95% at the family and between 85% and 90% at the order level , 80 and 
85% at the class and 77% to 80% at phyla.  After resolving based upon these parameters, the 
percentage of each bacterial and Fungal ID was individually analyzed for each sample providing 
relative abundance information within and among the individual samples based upon relative 
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numbers of reads within each.  Evaluations presented at each taxonomic level, including 
percentage compilations represent all sequences resolved to their primary identification or their 
closest relative (Stephenson et al., 2010; Dowd et al., 2008; Andreotti et al., 2011). 
9. Glycemic response analysis 
9.1. Subjects and study design 
Subjects from previous study IRB#09454 were invited to participate in a glucose 
response analysis under IRB amended on November 10, 2010. Participants were healthy 
overweight men, age18-45 years with body mass index (BMI) (25-44), non-vegetarian, non-
athletes, and non-smokers, recruited voluntarily from the campus of the University of Illinois, 
Urbana-Champaign. Twenty four subjects were recruited with a mean age of 31 (23-45) years 
with a mean BMI of 29 (26-38) and with normal serum triglycerides levels (<200 mg/dL). 
Subjects were asked to watch a video with the procedures to be performed in the study and sign a 
new informed consent. From the 24 subjects enrolled, 19 subjects finished the entire study and 
were considered for the analysis. The main reasons for withdrawal were inconveniences on work 
schedules and weather conditions. Participants were asked to participate in three repetitions of 
the glycaemic curve assessments on three different days (at least one week apart). Subjects were 
asked to fast for 12 h prior each meeting and each subject consumed a different treatment per 
repetition (low glycinin soymilk (LGS), conventional soymilk (S) or bovine milk (M)). They 
also participated in a BMI evaluation, one day diet record and a demographic interview in every 
repetition. 
9.2. Glucose curve assessment 
Subjects received instructions of how to use the glucometer (One Touch Ultra) and were 
asked to wash and dry their hand before each prick. Subjects consumed within 10-15 min 250 
40 
 
mL of milk containing same amount of carbohydrates, fat, energy and protein and were 
compared with the bovine milk response Table 4. Capillary finger-stick blood samples (1 
µl/sample) were taken in the fasting state (0 min) and 15, 30, 45, 60, 90, and 120 min after the 
start of the consumption of milk. Glucose levels were measured using a calibrated One Touch 
Ultra
® 
glucometer. According to Solnica et al., (2003) One Touch glucometers have acceptable 
performance and standard deviation from laboratory analysis <10%. The positive area under the 
curve (AUC) changes in blood glucose was computed by the trapezoidal method. The AUC was 
calculated for all variables measured by using the trapezoidal method (GRAPHPAD PRISM, 
version 4.00 (GraphPad Software, San Diego CA). Incremental AUC (iAUC) was considered as 
the AUC above baseline.  
The glucose curve shapes were classified following the definition of Tschritter et al. 
(2003). When plasma glucose increases to the maximum after 30-90 min and decreased until 120 
min is a “monophasic” plasma glucose curve. If glucose shapes reaches a nadir after an initial 
increase again > 0.25 mmol/L (4.5 mg/dL) until 120 min is classify as “biphasic” plasma glucose 
curve. If three glucose peaks are observed (>0.25 mmol/L minimum increment) was considered 
“triphasic”. 
Table 4. Nutrient composition of 250 mL of treatments 
Content in 250 mL S LGS M 
Calories (Cal) 105 ± 0.5 103 ± 0 93 ± 0.1 
Fat (g) 3.5 ± 0.2 3.5 ± 0 3.6 ± 0 
Carbohydrates (g) 11 ± 0.5 11 ± 0.6 8 ± 0 
Dietary Fiber (%) <1 <1 <1 
Protein (g) 7 ± 0.2 7 ± 0.1 7 ± 0.1 
Calcium (mg) 330 ± 3 350 ± 2.5 223 ± 2 
    *Data are Means ± STD. 
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10. Statistical analysis 
 Statistical analyses were conducted using SAS version 9.2. (SAS institute, Cary, NC). 
Relative differences, as percentage changes from baseline, were calculated for body fat, body 
lean mass, total cholesterol, serum triglycerides, serum ox-LDL, CRP, plasma interleukin-6, 
serum antioxidant capacity, plasma leptin, and plasma adiponectin. Calculation of relative 
differences was made by means of the following equation:  
 
Relative difference (%) = [(month 3-baseline)*100] / baseline] 
 
Data normality was analyzed with box plots, stem leaf diagrams, residual plots and 
Shapiro-Wilks tests. Not-normally distributed data were transformed to meet the assumption of 
normality for further analysis. Subject characteristics at baseline, energy intake and physical 
activity were analyzed by one-way ANOVA test. Changes in body fat accumulation, body lean 
mass, and biochemical parameters were analyzed with a mixed procedure with nested random 
effect model considering the influence of age, initial BMI and physical activity. Treatment 
effects per variable were compared using SAS contrast statements. Weight changes and nutrient 
intake were analyzed by a general linear model (GLM) using analysis of variance for repeated 
measurements.  
Mixed model with random effect (subjects) was also used for results of BMD, BMD T-
scores and q-PCR microbiota composition and pyrosequencying results.  Influence of age, initial 
BMI, kilocalorie intake and physical activity were considered for bone density analyses. 
Influence of initial BMI, changes in body fat, plasma adiponectin, oxidized LDL, physical 
activity, interleukin-6 and antioxidant capacity were considered for intestinal microbiota 
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analyses. Treatment effects per variable were compared using SAS contrast statements. T-tests 
were performed to determine the changes from baseline within treatments in microbiota 
composition data. All statistics are presented as means ± SEM and two sided P-values < 0.05 
were considered significant. 
Glycemic index analyses were analyzed with Multivariate analysis of variance 
(MANOVA) considering the effect of subjects, treatments, initial fasting glucose, type of curve, 
BMI, age, serum triglycerides and dietary intake of energy, protein, carbohydrates and fat. 
Glycemic response per treatment throughout the time was analyzed using analysis of variance for 
repeated measurements. All statistics are presented as means ± SEM and two sided P-values < 
0.05 were considered significant. Power analyses for the entire study were performed with the 
program SPSS version 15.0 for Windows. 
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VI. RESULTS 
1. Chemical composition of soymilk and bovine milk treatments 
Chemical analyses of the test products revealed no significant differences in total energy, 
protein (14 g) and fat (7g) among soymilks and bovine’s milk (Table 5), but different 
concentration of β-conglycinin (LGS, 49.5%; S, 26.5%; and M, 0% of total protein) and glycinin 
(LGS, 6.0%; S, 38.7 %; and M, 0% of total protein) as measured by SDS-PAGE of the soymilk 
powders used to make the liquid products.  
The total isoflavones content was similar in the two soymilk products (P > 0.05) (Figure 
17), and as expected bovine’s milk contained less that 1 ppm of isoflavones. In addition, the 
concentration of amino acids between the two soymilks (Figure 17) was not significantly 
different (P > 0.05), eliminating any influence of specific amino acids. 
 
Table 5. Chemical composition of S, LGS and M 
Content in 500 mL S LGS M 
Calories (Cal) 209 ± 0.5 206 ± 0 186 ± 0.1 
Fat (g) 7 ± 0.2 7 ± 0 7 ± 0 
Carbohydrates (g) 23 ± 0.5 23 ± 0.5 17 ± 0.2 
Dietary Fiber (%) <1 <1 <1 
Protein (g) 14 ± 0.2 14 ± 0.1 14 ± 0.1 
Calcium (mg) 660 ± 3 699 ± 2.5 446 ± 2 
          *Data are Means ± STD per 500 mL of milk. 
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A.
 
Data are means ± SD (P > 0.05).  Total isoflavones concentration in bovine’s milk was < 1 ppm. B. Data are 
means ± SD, (P > 0.05). Differences in Thr, Ala, Gly, Ile, Leu, Tyr, Phe, Cys and Met between S and GLS were < 1 
mg/g. 
 
Figure 17. Isoflavones and amino acid concentrations of LGS and S. 
 
2. Compliance 
Subject compliance with consumption of test materials was high (95% of packages consumed 
per month on average) and there were no compliance differences among treatments. The caloric 
intake of the participants remained constant during the study. Energy consumption was 
estimated, on average, as 9908 kJ (2368 kcal) per day. Likewise, physical activity did not change 
during the period of study in any of the groups (P = 0.90).  No adverse events were reported by 
the subjects. The attrition rate was mainly due to return of the subjects to their home towns upon 
the University’s summer recess (Table 6). 
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Table 6. Withdrawal reasons IRB 09454 
Withdrawal reasons Subjects 
Change of domicile 10 
Dislike the treatment flavor 2 
Other 1 
Did not explained reasons 4 
*Original recruitment: 81 – 17 drops = Final # subject = 64 
 
3. Baseline characteristics 
Participants characteristics at baseline did not differ significantly among groups (Table 
7). Subjects were 32 ± 7 years, weighed 96.3 ± 15.2 kilograms, BMI of 29 ± 4, 27.6 ± 5% body 
fat and 0.94 ± 0.06 waist to hip ratio. The homogeneity of the baseline status of the participants 
provides the basis to make a reliable comparison among treatments in the target parameters. 
 
Table 7. Subject characteristics in the different treatment groups at baseline 
 
Characteristic 
 
Low glycinin soymilk 
(LGS) 
n = 19 
Conventional 
soymilk (S)  
n = 23 
Bovine's milk (M) 
 
n = 22 
Age (years)  33 ± 6 32 ± 8 32 ± 6 
Body weight (Kg)  95.8 ± 11.1 96.2 ± 17.3 97.0 ± 17.2 
BMI  29 ± 3 29 ± 4 30 ± 4 
Total Body Fat (%)  28 ± 3.5 27 ± 6.0 28  ± 5.6 
Waist-Hip ratio  0.95  ± 0.05 0.94  ± 0.07 0.94  ± 0.06 
                         *Data are means ± SD (P > 0.05) 
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4. Anthropometrics and body composition 
4.1 Anthropometrics 
Changes from baseline in anthropometric parameters and body composition are presented 
in Table 8. LGS, S and M waist-hip ratio changes after three months were 0.33 ± 0.45; -016 ± 
0.50 and 0.82 ± 0.35 respectively; however, these changes were not significant among treatment 
comparison (P = 0.454). Body mass index and weight changed in the same proportion, due to 
their direct relationship. The weight of the participants after LGS, S and M consumption were 
0.71 ±0.61 Kg, 0.29 ± 0.29 Kg and 1.30 ±0.52 Kg respectively, however did not differ 
significantly among treatments (P = 0.836 for weigh and P= 0.721 for BMI). 
4.2 Body fat and lean composition 
After three month of consumption, total lean composition changes were not significant (P 
= 0.201) for LGS (2.49± 0.72%), S (1.10 ± 0.52%) and M (1.60 ±0.47%) (Figure 18). On closer 
evaluation, lean changes in left arm, right arm, trunk, left leg and right leg were also non-
significant for all treatments (P>0.05) (Table 8). Relative total body fat accumulation was 
slightly less in LGS (1.66% ± 1.40) compared to S (1.90% ± 0.67) (P = 0.015), or M (3.85% ± 
0.68) (P = 0.011) (Table 8). Tendencies to accumulate less fat in different parts of the body in 
subjects consuming LGS beverage, were not significantly different, except for less fat 
accumulation in the right leg of subjects in the LGS group (Figure 19). Although this difference 
was statistically significant, its biological meaning needs to be determined by further studies. 
However, these results support in vitro and in vivo observations on the effect of -conglycinin on 
fat accumulation. Martinez-Villaluenga et al. (2008) observed that alcalase hydrolysates from 
45% β-conglycinin soybean exhibited higher inhibition of lipid accumulation than hydrolysates 
from conventional soybean (25% -conglycinin) and bovine milk in 3T3-L1 adipocytes (37.5%, 
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29.3% and 4%, respectively, P < 0.0001). Kohno et al. (2006) also concluded that consumption 
of β-conglycinin during 3 months reduced total body fat in pre-obese and obese subjects; 
however, no changes were observed in abdominal fat. This observation agrees with the results in 
our study in regards to trunk composition and waist-hip ratio. Furthermore, Moriyama et al. 
(2004) observed that β-conglycinin significantly reduced body weight in normal and obese male 
mice compared with casein. Additionally, Baba et al. (2004) determined that the daily 
consumption of 5 g of β-conglycinin maintained body fat ratio in healthy women. However, in 
our study there were not significant changes in body weight (P> 0.05).  
Although changes in body weight were not significant, there was a tendency of 
maintaining a higher total lean body in the LGS group which could explain the lesser 
accumulation of body fat. Studies in the literature report that the inclusion of soy protein in the 
diet can have an impact on weight loss or reduction of body fat after three months (Allison et al., 
2003); produce a mild effect on body composition in post-menopausal women after six months 
(Liu et al., 2010); significantly reduce weight and fat composition in diabetic patients after 
twelve months (Li et al., 2005); and combined with low-fat diet, can improve body composition, 
preserving muscle mass in pre-obese and obese people after six months (Deibert et al., 2004). In 
contrast, Anderson et al. (2005), Zemel et al. (2009) and St-Onge et al. (2007) did not find effect 
on weight reduction or body composition in obese people after consumption of soy protein.  
The reduction of fat accumulation in the present study was modest and had no impact on 
body weight. This was probably due to the short duration of the study and that the intake of total 
soy protein per day was only 14 g/day (5.94 g/day of β-conglycinin in LGS, 3.18 g/day in S and 
0 g/day in M).  
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Table 8. Percent change from baseline (% relative differences) at the end of the study in 
anthropometric parameters and body composition after consumption of LGS, S or M
1, 2
 
 
Anthropometric 
parameters 
LGS 
(%) 
S 
(%) 
M 
(%) 
P-value 
Waist-Hip ratio 0.33 ± 0.45 
a
 -0.16 ± 0.50 
a
 0.82 ± 0.35 
a
 0.454 
Body Weight 0.71 ± 0.61
a
 0.29 ± 0.46
a
 1.30 ± 0.52
a
 0.836 
BMI 0.71 ± 0.61
a
 0.29 ± 0.46
a
 1.30 ± 0.52
a
 0.721 
Total body fat 1.66 ± 1.40 
b
 1.90 ± 0.67 
a
 3.85 ± 0.68 
a
 0.017 
Left arm fat 5.37 ± 1.97 
a
 4.75 ± 1.88 
a
 5.58 ± 2.09 
a
 0.892 
Right arm fat -0.47 ± 1.93 
a
 4.34 ± 2.37 
a
 4.68 ± 1.58 
a
 0.672 
Trunk fat 3.76 ± 2.17 
a
 3.86 ± 1.90 
a
 6.63 ± 1.95 
a
 0.740 
Left leg fat 4.26 ± 1.43 
a
 3.43 ± 1.27 
a
 6.85 ±1.24 
a
 0.124 
Right leg fat 2.76 ± 1.62 
ab
 5.31 ± 1.71 
ac
 7.29 ± 1.52 
c
 0.023 
Total body lean mass 2.49 ± 0.72 
a
 1.10 ± 0.52 
a
 1.60 ± 0.47 
a
 0.201 
Left arm lean 0.37 ± 0.79 
a
 -2.10 ± 0.83 
a
 -0.88 ± 1.01 
a
 0.871 
Right arm lean 0.76 ± 1.37 
a
 0.11 ± 1.21 
a
 1.56 ± 0.94 
a
 0.659 
Trunk lean 0.75 ± 0.81 
a
 0.52 ± 0.87 
a
 -0.12 ± 0.98 
a
 0.135 
Left leg lean -0.87 ± 0.68 
a
 -1.61 ± 0.64 
a
 -1.17 ± 0.61 
a
 0.912 
Right leg lean -0.40 ± 0.66 
a
 -1.12 ± 0.58 
a
 -0.28 ± 0.74 
a
 0.899 
 
 1
 Values are Means ± SEM of relative differences from baseline, n = 64. 
 2
 Different letters in rows are statistically different (P < 0.05). 
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Figure 18. Body lean composition changes after three months of LGS, S and M consumption 
 
Figure 19. Body fat composition changes after three months of LGS, S and M consumption 
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4.3 Bone mineral density 
The effect of protein beverages on BMD is presented in Table 9. Total BMD, left arm, 
right arm, left leg, left ribs, right ribs, thoracic-spine (T-spine) , and lumbar-spine (L-spine) did 
not have significant changes in BMD after three months of consumption of LGS, S or M 
(P>0.05). However, in the right leg, we detected that the consumption of S produced a slight 
reduction in BMD (-0.014 ± 0.011 g/cm
2
) as compared to LGS (-0.042 ± 0.010 g/cm
2
) and M (-
0.019 ± 0.009 g/cm
2
), P=0.003. BMD in the pelvis showed a slight decrease with the 
consumption of M (-0.022 ± 0.020) compared with a slight increase in the LGS (0.013 ± 0.011) 
and S (0.001 ± 0.013) groups (P=0.032) (Figure 20). On average, total bone mineral density for 
the three treatments did not decrease more than 0.005 g/cm
2
 which represents, a minimum 
biological relevant impact in the short term.  
Figure 20. Bone mineral density changes after three months of LGS, S and M consumption 
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No subject in the present study had osteoporosis (BMD t-score <-2.5) and ten subjects 
presented osteopenia problems at baseline and after three months (BMD t-score -1.0 to -2.5) 
according to WHO (1994). The changes in BMD t-scores within each treatment were small but 
significant (P<0.0001), however, the relative difference from baseline among groups (Figure 21) 
were not significant (P=0.094). Figures 22.a, 22.b and 22.c show that most subjects had a healthy 
bone condition (BMD t-score > -1.0) and anyone changed from a healthy condition to osteopenia 
condition which allowed us to conclude that BMD t-scores were not affected either by the type 
of milk consumed.  On average, the participants consuming LGS (-0.05 ± 0.02), S (-0.01 ± 0.04) 
and M (-0.02 ± 0.03) showed healthier BMD t-scores (Figure 22) compared with the study 
developed by Lee et al. (2010), where normal and pre-diabetic men had BMD t-scores of -1.34 ± 
1.42 and -1.33 ± 1.30 respectively. More research is required with a longer term of consumption 
to better understand the effects of different soy protein profile on bone mineral density.  
 
Figure 21. T-score changes after three months of LGS, S and M consumption 
 
52 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Changes from baseline to month 3 are significant (p<0.0001) 
Figure 22. T-scores at baseline and after three months of consumption of LGS, S and M. 
 
53 
 
Table 9. Bone mineral density changes after three months of consumption of LGS, S and M. 
BMD 
Low glycinin 
soymilk 
Conventional 
soymilk Bovine milk 
Among 
treatments 
g/cm
2
 SEM g/cm
2
 SEM g/cm
2
 SEM P - value 
Total BMD -0.004 ± 0.004 -0.005 ± 0.006 -0.005 ± 0.006 0.058 
Left arm 0.008 ± 0.011 -0.009 ± 0.009 -0.003 ± 0.009 0.170 
Right arm 0.018 ± 0.010 -0.013 ± 0.011 0.009 ± 0.006 0.506 
Left Leg -0.008 ± 0.010 -0.007 ± 0.011 -0.027 ± 0.008 0.590 
Right Leg* -0.042
b
 ± 0.010 -0.014
a
 ± 0.011 -0.019
b
 ± 0.009 0.003 
Left Ribs 0.005 ± 0.013 -0.004 ± 0.009 0.046 ± 0.016 0.512 
Right Rib -0.005 ± 0.010 -0.001 ± 0.009 0.017 ± 0.010 0.813 
T-Spine 0.022 ± 0.010 -0.004 ± 0.015 0.013 ± 0.012 0.332 
L-spine 0.019 ± 0.013 0.023 ± 0.015 -0.015 ± 0.025 0.278 
Pelvis* 0.013
a
 ± 0.011 0.001
a
 ± 0.013 -0.022
b
 ± 0.020 0.032 
*Different letters in rows are significantly different (P<0.05). 
 
The changes in BMD observed in the present study after the consumption of LGS for 3 
months can be considered biologically insignificant. The decreases for all treatments were on 
average less than 0.005 g/cm
2
. The fact that LGS and S contain similar isoflavones content but 
different protein profiles, agree with the theory that the beneficial effects of soy products in bone 
health may be due to the synergistic action of proteins profile and isoflavone content (Arjmandi 
et al., 1998; Bawa, 2010; Potter et al., 1998). In this study, the high level of β-conglycinin and 
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low level of glycinin in LGS did not produce a significant effect on bone change. Other studies 
support the protective effect of the isoflavone content independent from the soy protein profile in 
rats after 91 days (Picherit et al., 2001), in mice (Droke et al., 2007) and in post and 
premenopausal Western women (Ricci et al,. 2010). In concordance, Alekel et al. (2000) 
compared the bone effect of isoflavone-rich soy, isoflanove-poor soy and whey protein during 24 
weeks in perimenopausal women concluding that only isoflavone-rich soy ameliorated bone loss 
from lumbar spine. Other studies simply conclude that the consumption of whole soy products 
containing isoflavones reduce the risk of osteoporosis (Scheiber et al., 2001). On the other hand, 
Nagata et al., (2002) did not find any association of soy or soy-isoflavones intake with bone 
mineral density. Moreover, Wangen et al. (2000) did not observe any clinically important bone 
turnover after diets supplemented with soy-isoflavone for three months in pre and 
postmenopausal women. The lack of biologically relevant changes in BMD in our subjects may 
be attenuated by their overweight condition because there is some evidence that obesity has a 
protective effect against bone loss (Cifuentes et al., 2003; Wearing et al., 2006; El Maghraoui et 
al., 2010).  
Other factors like age, initial BMI, kilocalorie intake and physical activity did not have an 
influence in BMD in most parts of the body; however, age had an effect in pelvis (P=0.021) and 
left rib (P=0.006). These BMD changes showed slightly higher reductions in subjects older than 
35 years.  
5. Diet Records 
Compliance was good for each of the three groups (>94% for all treatments) and all 
subjects effectively provided information about their diet intake. Dietary intake of specific food 
products increases calcium absorption and bone mineral density (Roberfroid et al., 2010) and 
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factors such, age, BMI (El Maghraoui et al., 2010), physical activity, dietary vitamin D (Cooper 
et al., 2009), dietary calcium, phosphorus (Varley et al., 2010), among others are influencing 
bone health. Despite the conclusion of Noakes et al, (2005) affirming that high protein diets 
reduce bone calcium absorption and increase urinary calcium excretion, Heaney and Layman 
(2008) concluded that higher protein diets have benefit on bone mass with proper calcium intake.  
As shown in Tables 10, 11 and 12, the intake of dietary protein with consumption of LGS, S and 
M exceeded the dietary reference intake (DRI) for adult men of 56 g/day, however, none of the 
groups met the recommended calcium intake of 1000 mg/day or the vitamin D intake (200 
IU/day). The intake of these three nutrients were not different among treatments which allowed 
us to discard any influence of total protein (Figure 23), calcium (Figure 24) and vitamin D 
(Figure 25) intakes on changes in bone mineral density during the short term of consumption. 
Doubts about a low calcium bioavailability in the soy protein beverages (Heaney et al., 2000) is 
not a concern in the present study due to considerable evidence supporting that calcium 
fortification of soy protein beverages with calcium carbonate has an equivalent effect as bovine 
milk (Zhao et al., 2005; Tang et al., 2010). The slight reduction in BMD (<0.005 g/cm
2
) may be 
due to the lack of adequate dietary calcium and vitamin D, but it was not related to any of the 
treatments. The reduction in sodium, vitamin C and magnesium intake in the LGS group was the 
major difference in nutrient intake. We hypothesize that this change may be due the replacement 
in the consumption of certain food products like orange juice or soups by the protein beverage. 
The high level of sodium intake among all participants is within the regular average intake of 
American adult population (4000-5000 mg/day). However this exceeds the American Heart 
Association and the Institute of Medicine recommendations of sodium consumption no greater 
than 1500 mg/day (USDHHS:NIH, 2006).   
56 
 
 
Table 10. Macronutrient intake during three months of consumption of LGS, S and M. 
 
Time Baseline Month 1 Month 2 Month 3 TRT/ 
time 
effect                  
P-
value 
Intake 
/day 
LGS S M 
 P-
value* LGS S M 
 P-
value
* 
LGS S M 
 P-
value* LGS S M 
 P-
value* 
Energy 
(Kcal) 
 
2904 
±329 
2690 
±435 
1930 
±176 
0.20 
2615± 
267 
2695 
±389 
2023 
±235 
0.29 
2244 
±295 
2135 
±124 
2248 
±197 
0.96 
2395 
±244 
2542 
±193 
1892 
±212 
0.10 0.13 
Protein 
(g) 
 
108 
±9 
89 
±7 
76 
±8 
0.04 
95 
±11 
91 
±5 
77   
±9 
0.39 
89 
±10 
79 
±4 
79 
±9 
0.49 
97 
±12 
94 
±6 
69  
±7 
0.02 0.17 
CHOS 
(g) 
 
377 
±51 
268 
±19 
243 
±24 
0.03 
320 
±36 
330 
±48 
237 
±26 
0.21 
267 
±38 
250 
±18 
266 
±25 
0.92 
307 
±36 
299 
±27 
234 
±28 
0.24 0.05 
Fat (g) 
 
 
109 
±14 
94 
±10 
69  
±8 
0.07 
99 
±11 
110 
±21 
81 
±12 
0.43 
86 
±15 
88 
±6 
91 
±11 
0.99 
85   
±9 
102 
±9 
69 
±8 
0.02 0.09 
Dietary 
fiber 
(g) 
30   
±3 
15   
± 1 
14  
±1 
0.09 
21   
±3 
22 
±4 
17   
±2 
0.40 
20  
±3 
16  
±1 
15  
±2 
0.20 
23   
±2 
18  
±2 
14  
±2 
0.17 0.62 
*P-value of differences among treatments. Data excludes treatment consumption (See treatment composition in Table 4) 
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Table 11. Minerals intake during three months of consumption of LGS, S and M. 
 
Time Baseline Month 1 Month 2 Month 3 Treatm
ent/time 
effect                  
P-value 
Intake 
/ day 
LGS S M 
 P-
value* LGS S M 
 P-
value* LGS S M 
 P-
value* LGS S M 
 P-
value* 
Ca 
(mg) 
 
825  
±217 
692  
±102 
639 
±100 
0.75 
783  
±128 
641    
±60 
559   
±83 
0.53 
700  
±118 
650  
±53 
607 
±64 
0.78 
744  
±90 
758  
±77 
553  
±58 
0.93 0.73 
Fe 
(mg) 
 
26    
±7 
13  
±1 
13   
±1.8 
0.05 
18    
±3 
13   
±1 
11   
±1 
0.17 
19   
±5 
12    
±1 
11.7  
±0.9 
0.08 
24   
±7 
14   
±1 
11    
±1 
0.03 0.19 
Mg 
(mg) 
 
200  
±41 
132 
±16 
91  
±12 
0.02 
178   
±29 
107  
±12 
90  
±11 
0.01 
181  
±37 
123  
±12 
97  
±11 
0.02 
170  
±33 
168  
±31 
82  
±10 
0.04 0.004 
P 
(mg) 
 
 
908  
±175 
681.3 
±93 
521  
±74 
0.15 
859   
±153 
564  
±47 
576  
±77 
0.13 
866  
±181 
641  
±54 
624  
±58 
0.16 
813  
±161 
719  
±72 
490  
±72 
0.09 0.65 
K 
(mg) 
 
1887  
±517 
1531  
±362 
1414  
±402 
0.16 
1498  
±461 
1060  
±642 
959  
±434 
0.20 
1477  
±434 
1145   
±286 
1030  
±351 
0.57 
1489  
±507 
2006  
±445 
921  
±393 
0.16 0.06 
Na 
(mg) 
 
5310  
±517 
4335  
±362 
4017  
±402 
0.16 
5143  
±461 
5107  
±642 
3820  
±432 
0.20 
3731  
±434 
4269  
±286 
4097  
±351 
0.57 
4428  
±507 
4665  
±445 
3614 
±393 
0.16 0.02 
Caffei
-ne 
(mg) 
 
167    
±40 
103  
±30 
1093 
±803 
0.28 
173    
±36 
114  
±33 
102  
±27 
0.29 
173  
±46 
139  
±38 
100  
±29 
0.31 
198  
±55 
549  
±388 
114  
±29 
0.44 0.52 
*P-value of differences among treatments. Data excludes treatment consumption (See treatment composition in Table 4) 
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Table 12. Vitamins intake during three months of consumption of LGS, S and M. 
 
Time Baseline Month 1 Month 2 Month 3 
TRT/ 
time 
effect                  
P-
value 
Inta
ke 
/day 
LGS S M 
P-
value* LGS S M 
P-
value* LGS S M 
P-
value* LGS S M 
P-
value* 
 
Vit D 
(IU) 
 
61   
±22 
61   
±21 
33  
±15 
0.65 
22   
±67 
23  
±7 
24  
±6 
0.81 
12   
±4 
22    
±7 
32  
±6 
0.12 
18  
±5 
21  
±9 
17  
±5 
0.87 0.49 
 
Vit C 
(mg) 
 
76   
±24 
68   
±11 
57  
±11 
0.59 
32    
±5 
37  
±7 
19  
±2 
0.05 
60    
±21 
44  
±10 
28  
±5 
0.21 
49  
±10 
37  
±6 
27  
±6 
0.13 0.0002 
Vit 
B12 
(µg) 
 
3.9    
±1 
3     
±1 
2  
±0.3 
0.19 
2      
±1 
3    
±1 
3    
±1 
0.50 
2     
±1 
2     
±0 
2    
±0 
0.99 
3    
±1 
2   
±0 
2   
±0 
0.38 0.52 
 
Vit K 
(IU) 
 
38    
±18 
18    
±4 
12    
±3 
0.24 
17    
±4 
13  
±2 
11  
±1 
0.33 
41  
±12 
22   
±5 
21  
±5 
0.10 
13  
±3 
21  
±4 
13  
±4 
0.42 0.17 
 
Vit E 
(IU) 
 
5      
±2 
3       
±1 
1.2  
±0.2 
0.06 
3     
±1 
3    
±1 
3     
±1 
0.51 
4      
±1 
3     
±1 
3    
±0 
0.45 
3    
±1 
3    
±0 
2   
±1 
0.32 0.41 
 
Vit A 
(IU) 
 
5681  
±1669 
2885  
±694 
2629  
±267 
0.11 
4548  
±1158 
4058  
±627 
2627  
±530 
0.22 
3861  
±1110 
3291  
±593 
3123  
±534 
0.88 
4467 
±938 
4102  
±999 
2501  
±303 
0.12 0.64 
*P-value of differences among treatments. Data excludes treatment consumption (See treatment composition in Table 4) 
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Figure 23. Main nutrient intake throughout the study (P > 0.05) 
 
 
Figure 24. Calcium and sodium intake         Figure 25. Vitamin D and C intake 
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6. Physical activity 
Most participants had a sedentary life style and are part of the 32% of the American 
population physically inactive. There were not significant changes in physical activity during the 
study, eliminating any influence from this factor in the results observed. Changes from baseline 
in strenuous (P = 0.489) and moderate (P = 0.209) physical activity did not change more than 
1h/week (Figure 26). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Moderate and strenuous physical activity changes 
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7. Lipid profile and adipokines 
7.1. Total serum cholesterol, serum triglycerides and fatty acid synthase (FAS) 
In agreement with Gardner et al. (2007), consumption of LGS and S had no impact on 
levels of serum total cholesterol and triglycerides. Total cholesterol after consumption of LGS, S 
and M was 16.6 ± 7.6%, -2.9 ± 5.3% and 10.8 ± 6.7% respectively (P = 0.32). A slight decrease 
in serum triglycerides was observed with LGS, S and M (-8.8 ± 10.7%, -10.0 ± 13.1% and -5.8 ± 
8.1% respectively, however the changes among treatments were not significant (P = 0.95) (Table 
13).  This may be explained by differences in the types of heat treatments used in commercial 
soymilk production which may alter the ability of soy protein to lower cholesterol. For example, 
ultra-heat treatment, AS Ultra High Temperature (UHT) used in the present study, can destroy 
the cholesterol-lowering capacity of soy protein (Hoie et al., 2006). In contrast, other soy protein 
studies have observed an important improvement in serum lipids after soy consumption (Borodin 
et al., 2009).  Fatty acid synthase was also analyzed and changes among treatments were not 
detected (P = 0.976). LGS, S and M changes were -18.6 ± 16.8%, -31.9 ± 11.5 and 40.0 ± 21.6% 
(table 11). Our results differed from a previous study developed by Martinez-Villaluega (2010) 
where purified peptides from β-conglycinin EITPEKNPQLR and RKQEEDEDEEQQRE 
inhibited FAS in vitro. 
7.2. Plasma adiponectin and leptin 
Weight loss has been associated with the reduction of plasma leptin (Yamashina et al., 
1998). Dietary interventions performed in this study did not lead to weight loss in overweight 
men which may explain the maintenance of leptin levels (Table 13). LGS (14.9 ± 4.5%) and S 
(2.0 ± 5.2%) increased plasma adiponectin while M (-7.8 ± 4.4) decreased it (Figure 27). The 
elevation in plasma adiponectin associated with LGS consumption could partially explain the 
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differences in body fat composition due to the hormonal regulatory property of this hormone on 
fatty acid catabolism. Adiponectin is inversely correlated to the content of body fat in adults 
(Diez and Iglesias, 2003). Marecki et al. (2010) suggested age-related differences in the role of 
adiponectin in pathological responses associated with obesity. Higher levels of plasma 
adiponectin in overweight men after 3 months of LGS consumption may also contribute to 
decreasing oxidative stress and inflammatory state. Iwabu et al. (2010) determined that 
adiponectin reduced oxidative stress through the induction of Ca
2+
 influx in skeletal muscle via 
AdipoR1 (Iwabu et al., 2010). Our results are also consistent with Martinez-Villaluenga et al. 
(2008), who determined in vitro that β-conglycinin induced more adiponectin expression in 3T3 
L1 adipocytes than glycinin. A recent study confirmed that β-conglycinin increases adiponectin 
levels in rats more than soy protein isolate (SPI) and casein (Tachibana et al., 2010). The 
increment in plasma adiponectin levels and the stability of plasma leptin after the consumption of 
LGS may have positively influenced energy expenditure without increasing satiety.  
 
Figure 27. Relative differences in plasma adiponectin after three months
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Table 13. Serum lipids, plasma leptin, C-reactive protein, tumor necrosis factor alpha and fatty acid synthase (FAS) at baseline and 
three months after consumption of the different types of LGS, S and M 
 
1
 Values are means per treatment per time. 
2
 Values are Means ± SEM of relative differences from baseline, n = 64. 
3
 Different letters in rows are statistically 
different (P < 0.05).  
4
 Variation probability among treatments. * Significantly different from baseline, P < 0.0001. 
Biomarker 
 LGS 
1
  S 
1 
  M 
1 
 Relative differences from baseline (%) 
2, 3
 
Baseline Month 3 Baseline Month 3 Baseline Month 3 LGS S M P-value
4
 
Total 
Cholesterol 
(mg/dL) 
 
299.9 ± 
24.5 
 
 
334.5 ± 
21.9
* 
 
 
396.3 ± 
33.6 
 
 
360.9 ± 
23.3
* 
 
 
313.3 ± 
22.9 
 
 
337.6 ± 
24.9
* 
 
 
16.6 ± 7.6
a 
 
 
-2.9 ± 5.3
a 
 
 
10.8 ± 6.7
a 
 
 
0.32 
 
 
Total 
Triglycerid
es (mg/dL) 
143.6 ± 
26.8 
 
 
128.9 ± 
36.6
* 
 
 
151.5 ± 
26.9 
 
 
135.5 ± 
23.9
* 
 
 
105.4 ± 
19.1 
 
 
90.1 ± 
12.5
* 
 
 
-8.8 ± 10.7
a 
 
 
-10.0 ± 13.1
a 
 
 
-5.8 ± 8.1
a 
 
 
0.95 
 
 
 
Leptin  
(ng/mL) 
 
13.6 ± 
1.9 
 
14.4 ± 
1.4
* 
 
14.9 ± 
2.1 
 
16.8 ± 
1.9
* 
 
16.2 ± 
3.9 
 
18.5 ± 
4.2
* 
 
6.6 ± 17.8
a 
 
11.8 ± 5.9
a 
 
20.4 ± 7.4
a 
 
0.66 
 
C-Reactive 
protein 
(ng/mL) 
 
2022.9 
± 297 
 
1903.7 ± 
367
* 
 
1200.1 
± 258 
 
978.4 ± 
166
* 
 
1718.8 
± 316 
 
1878.1 ± 
374
* 
 
-6.6 ± 10.5
a 
 
 
-19.7 ± 6.0
a 
 
 
1.0 ± 6.8
a 
 
 
0.96 
 
 
Fatty acid 
synthase 
(mg/mL) 
1.89 ± 
0.90
*
 
1.84 ± 
1.11
*
 
5.83 ± 
0.97 
4.58 ± 
0.96
*
 
2.77 ± 
0.71 
4.11 ± 
1.12
*
 
-18.6 ± 16.8
a
 -31.9 ± 11.5
a
 
40.0 ± 
21.6
a
 
0.98 
 
Tumor 
Necrosis 
Factor α 
(pg/mL) 
1.2 ± 
0.3 
1.2 ± 0.6 
0.8 ± 
0.1 
0.7 ± 0.1
*
 
1.4 ± 
0.3 
1.4 ± 0.4 -18.3 ± 17.8
a
 -12.8 ± 14.2
a
 -8.6 ± 8.7
a
 0.61 
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8. Oxidative stress 
8.1. Oxidized LDL 
Consumption of LGS for three months significantly reduced the levels of ox-LDL (Table 
14).  Consumption of S and M also reduced oxi-LDL; however, this reduction is smaller than the 
impact of LGS consumption (Figure 28).This reduction is similar to the therapeutic effect of 
statins when used in patients with hypercholesterolemia, in which the statin drug reduces up to 
43% of ox-LDL (Nakhjavani et al., 2010). A possible reason for this reduction in ox-LDL is that 
peptides from β-conglycinin have cell protective properties against oxidation by increasing the 
expression of thioredoxin 1 and cyclophilin B (Castiglioni, 2003; Van Ee, 2009), and preventing 
retinal ganglion cell death (Caprioli et al., 2009). It has been also found that soy peptides, not the 
amino acid content, reduced the oxidative stress in rats (Takenaka et al., 2003).  
 
 
 
 
 
 
 
 
Figure 28. Relative difference in oxi-LDL after three months 
 
The strong reduction in ox-LDL, as in the present study, has been considered independent 
of BMI in men (Weinbrenner et al., 2006).  However, our data show that subjects with lower 
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BMI presented higher reduction in oxi-LDL than those with higher BMI levels. Also younger 
subjects reduced more Oxi-LDL than the older participants (Table 15). Flavonoids present in 
soymilk can also exert an additional protective effect against LDL oxidation by binding directly 
to LDL molecules or acting as radical scavengers (Wu et al., 2009). Based on our results, one 
can speculate that β-conglycinin may protect against plaque development by inhibiting oxi-LDL, 
and that by reducing systemic oxidative stress may also decrease risk factors for diabetes and 
obesity (Njajou et al., 2009). 
8.2. Antioxidant capacity 
Oxidative stress is strongly associated with type 2 diabetes and cardiovascular mortality 
and serum antioxidant capacity may play an important role in metabolic syndrome prevention 
(Beydoun et al., 2011). Both soymilk types improved serum antioxidant status compared to 
bovine milk (Table 14).  However, the higher -conglycinin content in soymilk did not provide 
additional improvement (Figure 29).   In agreement with our results, a previous study comparing 
soybean and casein proteins determined that mice fed soybean protein lowered oxidative stress 
and increased antioxidant enzymes more than casein (Gu et al., 2008). Similarly, soy 
consumption reduced plasma malondialdehyde (MDA) and increased plasma total antioxidant 
capacity (TAC) levels in postmenopausal women with metabolic syndrome (Azadbakht et al., 
2007). Antioxidant properties of soymilk have been attributed to soybean peptides (Suetsuna et 
al., 1999) or specifically histidine-containing soybean peptides released after gastrointestinal 
digestion which act as hydroxyradical scavengers (Chen et al., 1998). However, the parental 
protein from which these peptides derived has not been reported. Soymilk also contains other 
nonpeptidic antioxidants such as tocopherols, isoflavones and phenolic acids which may 
contribute to its antioxidant capacity (Takahashi et al., 2005).  
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Figure 29. Relative difference in antioxidant capacity after three months. 
 
Table 14. Oxi-LDL and antioxidant capacity at baseline and at the end of the study. 
Biomarker n Treatments 
Baseline 
U/mL 
Month 3 
U/mL 
Relative  
difference 
(%) 
P-value
1
 Contrasts 
Serum 
Oxidized 
LDL 
15 
LGS 0.074 0.019 -61.3 
0.0019 
S vs. LGS = 
0.0007  SEM 0.012 0.004 3.8 
20 
S  0.099 0.051 -36.4 LGS vs. M  
< 0.0001 SEM 0.039 0.014 7.1 
16 
M 0.144 0.136 -12.8 S vs. M = 
0.8568 SEM 0.062 0.061 5.2 
Biomarker n Treatments 
Baseline 
µmoL 
Trolox/ml 
serum 
Month 3 
µmoL 
Trolox/
ml 
serum 
Relative 
difference 
(%) 
P-value Contrasts 
Serum 
Antioxidant 
Capacity 
18 
LGS 16.28 19.22 18.5 
< 0.0001 
S vs. LGS = 
0.9051 SEM 0.59 0.79 3.5 
22 
S 15.59 19.67 28.1 LGS vs. M  
= 0.001 SEM 0.67 0.84 4.6 
21 
M 17.02 9.46 -40.4 S vs. M  
<0.0001 SEM 0.58 1.37 9.7 
Data are means and SEM. 
1 
Statistical effect of treatment in changes in Oxi-LDL and antioxidant capacity. 
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Table 15. Oxi-LDL relative differences by BMI and age 
BMI Ox-LDL (RD) STD n P-value 
25-27 -46.9
b
 28.8 18 
0.004 28-35 -36.3
b
 39.0 27 
36-41 -9.1
a
 46.0 6 
AGE Ox-LDL (RD) STD n P-Value 
23-25 -52.8
b
 51.5 7  
 
0.046 
 
 
26-30 -33.6
a
 33.9 15 
31-35 -41.3
a
 35.3 11 
36-40 -41.9a 37.8 7 
41-45 -23.2
a
 36.3 11 
*P-vale of the comparison among groups  
9. Inflammation 
9.1 Plasma interleukin-6 
Body fat accumulation leads to a proinflammatory state accompanied by an increased 
expression of pro-inflammatory cytokines and chemokines in circulating monocytes which 
control fat accumulation and leptin expression in human adipocytes (Christie et al., 2010). The 
plasma concentration of IL-6, due to the consumption of LGS (-22% ± 9, P = 0.025) or S (-26% 
± 5, P = 0.014) were also reduced in comparison to M (10% ± 12).  
Our previous in vitro studies demonstrated that alcalase hydrolysates from -conglycinin 
enriched soybean genotypes exhibited an anti-inflammatory effect through inhibition of 
NO/iNOS and PGE2/COX-2 pathways in LPS-stimulated RAW 264.4 macrophages. However, 
the effect of -conglycinin on pro-inflammatory mediators in overweight people has not been 
reported. In the present study we observed that consumption of soymilk was associated with 
reduced plasma IL-6 levels unlike in bovine milk consumption (Figure 30).  Our results are in 
agreement with Christie et al. (2010) which determined that three months of soy supplementation 
in obese postmenopausal women reduced circulatory IL-6.  
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Figure 30. Relative difference in plasma inteleukin-6 after three months 
 
9.2. Plasma C-reactive protein and tumor necrosis factor alpha 
Contrary to plasma IL-6, relative differences of CRP and leptin levels in plasma were not 
affected by treatment in agreement with Maskarinec et al. (2009) who demonstrated that a high-
soy diet for 3 months did not modify the levels of inflammatory markers in overweight 
individuals. Plasma CRP tended to decrease with LGS, S and M after three months (-6.6 ± 11%, 
-19.7±6% and 1.0± 7% respectively). However, changes were not significant among the 
treatments (P = 0.96). TNFα presented similar behavior (P = 0.61) (Table 13). 
10. Gut microbiota composition 
10.1. General gut microbiota 
Evidence that gut microbiota composition can differ between obese and lean individuals led the 
hypothesis that gut microbiota manipulation may be one alternative mechanism to improve this 
epidemic. According to recent studies microbiota may play a strategic role in susceptible 
populations like the obese (Ley, 2010) and type 2 diabetic populations (Larsen et al., 2010). Few 
researchers have investigated the impact of soy products or soy proteins in gastrointestinal 
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microbiota. Based on the primers used in this study, microbiota density increased after the 
consumption of LGS (88.4 ± 28%), S (77.2 ± 31%) and M (70.1 ± 31%). However, all 
treatments provided the same behavior (P = 0.358) (Figure 31). The prevalence of bacteria in the 
GI tract dependent on several factors, such as pH, peristalsis, redox potential, bacterial adhesion, 
bacterial co-operation and antagonism, mucin secretion, diet and nutrient availability among 
others. More density is not necessarily a positive effect; bacterial overgrowth has a negative 
impact on the function and morphological structure of the small bowel (Bures et al., 2010), 
however, our results may carry positive effects because microbiota density increment was 
determined in feces. 
 
 
 
 
 
 
  *P-value within treatments. **P-value among treatments. 
Figure 31. Relative changes in universal microbiota after three months 
 
The Bifidobacteria changes in LGS (-98 ± 1%) and S (-76 ± 13%) tended to decrease. 
However, under the condition of this study this change was not significantly different from 
**(P=0.358) 
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bovine milk (240 ± 85%) (Figure 32). Confusing tendencies were observed in Lactobacillus 
changes (Figure 33) where LGS reduced while S and M increased the Lactobacillus population 
but these changes were not different within or among groups. This phenomenon may be 
interpreted in the right direction considering the existing evidence that Lactobacillus in obese 
populations is higher than in lean populations (Armougon, 2009).  
According to Santacruz et al. (2009) physical activity has an impact on gut microbiota. In 
our study, physical activity did not have an effect on gut microbiota changes which was expected 
due the physical inactivity of the subjects during the study. Santacruz et al. (2009) also found 
that overweight adolescent with higher fecal total bacteria and lower Lactobacillus and 
Bifidobacteria experienced higher weight loss which is relatively comparable to what happened 
after the consumption of soymilk in our study. 
 
*P-value within treatments. **P-value among treatments. 
Figure 32. Relative changes in Bifidobacteria after three months 
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*P-value within treatments. **P-value among treatments. 
Figure 33. Relative changes in Lactobacillus after three months 
 Bacteroides have a positive association with plasma biomarkers of lipid metabolism; 
higher gut Bacteroides composition is associated to higher HDL-cholesterol and lower 
triglycerides levels (Santacruz et al., 2010).  Nadal et al. (2009) confirmed a relationship 
between Bacteroides and Clostridium with weight loss. Subjects with higher weight loss had 
more Bacteroides and Clostridium in their microbiota profile than those who loss less weight. In 
our study, subjects did not lose weight with any treatment and changes in Bacteroides were not 
significant (Figure 34) which agrees with the studies previously mentioned. Alterations in 
Bacteroides number and its specific effect in body weight may be an interesting target for future 
human studies. 
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*P-value within treatments. **P-value among treatments. 
Figure 34. Relative changes in Bacteroides after three months 
 
 
Our results suggest that the consumption of LGS, S and M have similar impact on total 
microbiota, Bacteroides, Bifidobacteria and Lactobacillus after three months. These findings 
agree with Piacentini et al. (2010) who compared the effect of bovine and soy-based formula in 
infants for one month. They concluded that soymilk and bovine milk has a comparable impact in 
species biodiversity in infants and also concluded that soymilk does not alter the general 
intestinal flora of infants but it decreased Bifidobacteria.  
10.2. Genera diversity analysis 
High-throughput sequencing of the hypervariable V1-V3 region of the 16S rRNA was 
performed. Samples (n=384) were sequenced obtaining 1.88 million total sequences and 1.2 
million sequences after trimming for selection of the high quality sequences. Sequences 
presented an average length of 491bp.  Between 4600-4700 sequences were used and the 
taxonomic tree at the phyla level generated is shown in Figure 35. The diversity indices ACE and 
Chao1 showed very high sample richness estimating the potential OTU’s that would be seen if 
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the sequence is completed. OUT 3% analysis showed a significant reduction in diversity within 
groups (P<0.05) (Table 16). Approximate 50% of total diversity is represented by the sequences 
in this study and all treatments showed a slight reduction in the species diversity. These findings 
agree with Turnbaugh et al. (2009) who determined that obesity reduces bacterial diversity. 
Figure 36 shows the high quality of sequencing coverage (curves close to asymptote) indicating 
that overall diversity among people becomes more similar after three months of consumption.  
 
 
 
 
 
 
 
 
Figure 35. Taxonomic tree at the phyla level 
Table 16. Microbiota diversity 
TRT Seq used OUT 3% ACE 3% Chao1 3% 
  B T3 B T3 
P-
value* 
B T3 B T3 
LGS 
4687 
(259) 
4730 
(224) 
1064 
(207) 
938 
(147) 0.004 
2191 
(783) 
1606 
(337) 
1749 
(473) 
1396 
(271) 
S 
4689 
(336) 
4671 
(175) 
1019 
(173) 
915 
(80) 0.005 
2065 
(586) 
1653 
(268) 
1663 
(373) 
1386 
(148) 
M 
4604 
(490) 
4625 
(341) 
1043 
(207) 
923 
(142) 0.001 
2150 
(685) 
1539 
(337) 
1722 
(414) 
1365 
(244) 
 
Data are Means (STD). Operational taxonomic Units (OTU). OTU at 3% can show an identity at the species level of 
phylogeny. * P-value represents significant changes from baseline. B means baseline and T3 means after three 
months of consumption. Differences in OUT 3% among treatments were not significant (P = 0.227). 
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Figure 36. Rarefaction curves at baseline and after three months for LGS, S and M.  
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The majority of gut bacteria in mammals belong to the phyla Bacteroidetes and 
Firmicutes (Ley et al., 2008) and there is a significant amount of evidence saying that elevated 
Firmicutes content and lower Bacteroidetes content characterizes the obese gut microbiota (Ley 
et al., 2005; Turnbaugh et al., 2009; Armougom et al., 2009). Weight loss has been also directly 
related with a decrease in the Firmicutes/Bacteroidetes ratio (Ley et al., 2006). After the 
pyrosequencying analyses performed in this study, phylum changes after three months in 
Firmicutes, Bacteroidetes, Actinobacteria and Proteobacteria were not different among the 
treatments (P > 0.05). However, within treatments we were able to detect Firmicutes significant 
decreases with consumption of LGS (-3.9 ± 2.2%) and S (-5.8 ± 2%) and an increase with M (2.5 
± 2.9%).  On the other hand, Bacteroidetes abundance increased with the consumption of LGS 
and S (30.0 ± 10.6% and 29.5 ± 10.2%, respectively) (Figure 37).  
Additionally, our analyses detected an influence of age in the changes in Bacteroidetes (P 
= 0.029) and Firmicutes (P = 0.041). These findings agree with Mariat et al. (2009) who 
affirmed that Firmicutes/Bacteroidetes ratio increases with age, elevating the probabilities of 
gain weight. Initial BMI, changes plasma adiponectin, plasma ox-LDL, physical activity, plasma 
IL-6 and antioxidant capacity throughout the study were not a direct influence in phylum 
changes. Following the same trend, the Firmicute/Bacteroidetes ratio after three months of 
consumption tended to decrease with both soymilk treatments (LGS -1.9 ± 0.6; S -1.2 ± 0.5 and 
M 0.1 ± 0.6 ratio difference) (Table 17). These decreases in Firmicute/Bacteroidetes ratio may 
represent a potential weight lost in the medium or long term of consumption (Ley et al., 2006) 
and may have effects in obesity related conditions.  
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*P-value of the among treatment comparison 
Figure 37. Relative change in Firmicutes and Bacteroidetes abundance after three months 
 
Table 17. Firmicutes/Bacteroidetes ratio with LGS, S and M consumption 
Firm/Bac Baseline T3 Diff SEM 
Within 
treatment 
P-value 
LGS  6.8 4.9 -1.9 0.6 0.006 
S 6.8 5.6 -1.2 0.5 0.018 
M 6.4 6.5 0.1 0.6 0.847 
               *Significant changes P-value <0.05. Changes among treatments were not significant (P=0.757). 
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Our results showed that overweight and obese men phyla abundance at baseline and after 
three months is dominated by Firmicutes (81.1 ± 10.4% and 78.4 ± 10.6% respectively). The 
second dominant phyla was Bacteroidetes (16.9 ± 13.3% and 18.6 ± 13.2%) at baseline and 
month 3 respectively. Actinobacteria, Proteobacteria and Fusobacteria represent less than 1% of 
the gut microbiota profile (Figure 38).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Only major taxonomic groups are shown; these cover 90-100% of all reads assigned to phylum level. 
Figure 38. Dominant phyla aggregation intestinal microbiota in overweight and obese men 
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Actinobacteria abundance in young adults varies between 0.4-11.4% and Proteobacteria 
between 11-23% (Claesson et al., 2010). Our Actinobacteria results are within the literature 
limits for young individuals; however the Proteobacteria abundance of overweight and obese 
men is more comparable to gut microbiota of elderly individuals (~2%).   The phylum 
Actinobacteria contains Bifidobacterium spp., which has been considered beneficial for human 
gastrointestinal health. Proteobacteria phylum is a gram-negative bacteria group containing a 
rich-lipopolisaccharides (LPS) outer membrane and includes important pathogens like 
Salmonella, Vibrio, Escherichia, among others. LPS is considered pro-inflammatory indicator 
generated by gram-negative bacteria and high circulating levels have been related with obesity 
(Amar et al., 2008). Although Actinobacteria (P = 0.073) and Proteobacteria (P = 0.849) 
changes were not different among our treatments, a significant increment was observed in 
Actinobacteria with consumption of LGS (18.5 ± 3.5%; P = 0.006). Our previous results showed 
an apparent reduction in Bifidobacteria with the soymilk consumption which let us conclude that 
the increment in Actinobacteria is not due to Bifidobacteria abundance. On the other hand, 
Proteobacteria gut colonization significantly increased with the consumption of LGS (90.7 ± 
34%), S (132 ± 47.6%) or bovine milk (141.1 ± 50.9%) (Figure 39). The decrease in 
Actinobacteria -Bifidobacteria and increase in Proteobactria observed must be of special 
consideration due their relationship with type 2 diabetes (Wu et al., 2010; Larsen et al., 2010). 
Through a brief question about the bowel movement changes during the monthly interviews we 
determined no significant changes in defecation frequency (P=0.575) during the study (Figure 
40). Phylogenic abundance profile in Table 18 provides more specific description of the gut 
microbiota genera and species changes in this study. 
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*P-value of the among treatment comparison 
Figure 39. Relative change in Firmicutes and Bacteroidetes abundance after three months 
 
Changes in bowel movement were less than 1 time/day for all treatments 
Figure 40. Relative changes in bowel movements after three months 
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Table 18. Phylogenic abundance profile related with LGS, S and M consumption 
 
ABUNDANCE (%)   LGS   
S 
  
M   
 Phylum Genera Species B T3 P-value* B T3 P-value* B T3 P-Value* P-value** 
Bacteroidetes  15.54 17.97 <00001 16.32 20.37 0.0001 18.78 17.54 0.6153 0.777 
Bacteroides 11.11 13.78 0.658 9.03 9.90 0.498 10.83 11.29 0.066 0.261 
 
Bacteroides vulgatus 3.51 4.55 0.027 3.00 2.97 0.003 3.79 3.69 0.233 0.309 
Firmicutes   83.43 79.59 <0.0001 82.93 78.08 <0.0001 77.02 77.64 <0.0001 0.494 
Eubacterium 16.28 16.73 0.049 14.65 16.68 <0.0001 14.06 16.67 0.130 0.356 
Eubacterium rectale 9.36 9.72 0.166 9.19 11.05 0.016 9.28 10.98 0.644 0.518 
Eubacterium eligens 2.23 2.48 0.233 2.52 2.18 0.038 1.49 1.73 0.537 0.589 
Faecalibacterium 35.26 33.53 <0.0001 39.89 31.65 <0.001 30.02 24.97 0.0007 0.501 
Faecalibacterium prausnitzii 35.26 33.53 <0.0001 39.89 31.65 <0.001 30.02 24.97 0.0007 0.501 
Roseburia 6.27 6.38 <0.0001 7.35 5.34 <0.0001 5.22 6.71 0.0007 0.851 
Roseburia intestinalis 4.12 4.28 0.463 5.11 3.72 0.651 3.87 4.88 0.592 0.759 
Roseburia cecicola 2.15 2.10 0.002 2.25 1.62 0.000 1.35 1.83 0.038 0.417 
Ruminococcus 3.94 3.71 0.502 3.12 3.68 0.005 2.60 3.78 0.006 0.867 
Coprococcus 0.54 0.40 0.003 1.27 1.15 0.000 0.99 0.89 0.006 0.754 
Lachnospira 0.79 0.95 0.776 0.49 0.76 0.025 0.67 0.62 0.648 0.713 
Pseudobutyrivibrio 0.42 0.25
a
 0.0009 0.37 0.24
b
 0.001 0.37 0.20
a
 0.011 0.001 
Clostridium 15.85 13.22 0.002 11.76 13.73 <0.0001 18.20 17.91 <0.0001 0.497 
Clostridium orbiscindens 2.77 2.30 0.800 2.17 2.70 0.115 2.68 3.10 <0.0001 0.521 
Clostridium bolteae 1.98 1.60 0.081 1.57 1.84 <0.0001 2.92 2.72 0.016 0.427 
Clostridium methylpentosum 1.28 1.08 0.327 1.06 1.02 0.092 1.65 1.66 0.004 0.621 
Clostridium aminophilum 2.03 1.62
b
 0.071 0.90 1.33
a
 0.000 1.15 0.84
b
 <0.0001 0.024 
Clostridium symbiosum 1.33 1.24 0.390 1.01 1.04 0.025 1.52 1.51 0.422 0.703 
Clostridium saccharolyticum 0.83 0.59 0.775 0.77 0.82 0.813 1.54 1.48 0.523 0.260 
Actinobacteria  0.10 0.13 0.078 0.13 0.09 0.006 0.29 0.19 0.076 0.073 
Proteobacteria  0.65 2.24 0.022 0.55 1.22 0.013 0.87 1.87 0.009 0.849 
 
* P-value of changes within treatment. ** P-value of changes among treatment. B mean Baseline and T3 means after three months of consumption. Different letter in rows represent significant changes 
from baseline among treatments. 
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11. Glycemic response 
LSG, S and M were processed and stored under the same conditions to eliminate bias due 
to treatment preparation. Analysis of low glycinin soymilk (49.9% β-conglycinin) and 
conventional soymilk (26.5% β-conglycinin) resulted in GI of 41.0±7.2 and 40.4 ±9.6, 
respectively. The effect of both soymilk treatments was compared against bovine with GI of 29.2 
±6.1 in overweight men. All beverages are low glycemic index products according to the 
American Diabetes Association (ADA, 2011) (GI of 55 or less). The international tables of 
glycemic index also classify our treatments as low GI food product.   
Glucose maintenance (Barclay et al. 2010; Stevenson et al., 2005), better glycemic 
responses (Jenkins et al., 2002) and increase in satiety have been associated with low GI 
products. In contradiction, other authors did not find differences in glucose response in short 
term low GI food consumption (Jenkins et al., 2011; Kurotobi et al., 2010; Isken et al., 2010; 
Cocate et al., 2010; Nuttall et al., 2011). 
Animal studies developed by Tachibana et al., (2010) and Moriyama et al. (2003) 
affirmed that β-conglycinin improves glucose levels more than casein. Our results contradict 
such findings, with no differences in postprandial blood glucose response among the high, 
regular and none β-conglycinin treatments throughout the 120 min of the analysis (P = 0.338) 
(Figure 41). The maximum glucose peak was observed at 45 min after consumption for all 
treatments. We also failed to prove that consumption of food products with similar carbohydrate 
content but different GI’s, as shown in our soymilk and bovine beverage, promote different 
postprandial blood glucose response as shown by Parillo et al., (2010).   
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Data are: Means ± SEM.  *(P < 0.05). Time X treatment effect (P = 0.331) 
Figure 41. Glycemic response of LGS, S and M. 
 
The only difference observed in the postprandial glucose response throughout the time 
among treatments was a slight lower blood glucose concentration at minute 60 with bovine milk 
(P = 0.021).  However, after 75 minutes all treatments tended to stabilize the glucose 
concentration between 90-100 mg/dL. LGS and S showed less monophasic than biphasic glucose 
curves. However, the glucose curve type did not influence the glycemic response (Table 19). 
According to Tschiritter et al. (2003) biphasic glucose curves are more associated with normal 
glucose tolerance than monophasic curves, and most of the curves observed with soymilk 
consumption were biphasic. The influences of BMI (P =0.177), age (P = 0.712) and serum 
triglycerides (P = 0.617) were explored and none of them had an effect in postprandial glucose 
response under the condition of this study.  
* 
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Nutrient intake analysis generated through a one-day diet record, for assessing of energy, 
carbohydrates, fat and protein intake were analyzed and showed no effect on postprandial 
glucose, except for protein intake (P = 0.018).  However the difference of 6 g/day of protein 
intake was not enough to produce significant changes in glycemic response among treatments 
(Table 19). LGS, S and M presented fasting blood glucose of 91.1 ± 1.3 mg/dL, 94.1 ± 2.0 
mg/dL and 91 ± 2.0 mg/dL respectively. These small differences were influencing the 
postprandial blood glucose response (P = 0.0006).  However, the association with glycemic 
response is not clear. The power analysis for the postprandial glucose response was 96% 
increasing our confident about our results and confirming the proper amount of subjects used for 
this study. After an analysis of the glycemic response using low glycinin soymilk, conventional 
soymilk and bovine milk we can conclude that β-conglycinin does not have an effect in blood 
postprandial glucose response in overweight and obese mean. 
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Table 19. Glycemic response of LGS, S and M. 
TRT LGS M  S P-value* 
n 16 16 14 
 
Glycemic index 41.0 ± 7.2 40.4 ± 9.6 29.2 ± 6.1   
F  a  c  t  o  r  s      o f      I  n  f  l  u  e  n  c  e 
Fasting glucose (mg/dL) 91.1 ± 1.3 94.1 ± 2.0 91.2 ± 2.0 0.0006 
Curve type 
Monophasic 5 6 5 
0.072 Biphasic 9 7 8 
Triphasic 1 1 3 
BMI 
 
29 ± 1 29 ± 1 30 ± 1 0.177 
Age years 30.4 ± 1.4 30. 1 ± 1.6 30.1 ± 1.5 0.712 
Serum 
Triglycerides 
(mg/dL) 78.9 ± 11.3 78.1 ± 12.1 80.2 ± 11.4 0.617 
Dietary 
energy 
Kcal 2472 ± 251 2699 ± 192.3 2611 ± 282 0.219 
Dietary 
CHOs 
g 366.7 ± 41.3 348.5 ± 34.2 340.6 ± 39.2 0.350 
Dietary 
protein 
g 103.9 ± 9.6 102.4 ± 7.5 96.4 ± 10.3 0.018 
Dietary 
fat 
g 121.9 ± 16.8 98.7 ± 9.5 97.3 ± 14.7 0.795 
* P-values of the influence of variables in the glycemic index response (MANOVA). Data are Mean ± SEM. The 
treatment effect in glycemic index was not significant (P = 0.338)
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VII. SUMMARY AND INTEGRATION 
Obesity has many correlated negative effects in human health and affect a wide range of 
the U.S. population, approximately ¾ of the adult men population is obese or overweight. The 
use of dietary bioactive compounds in soybean has been studied as new strategic solutions to this 
epidemic problem; the present study focused its effort to evaluate the effect of β-conglycinin in 
body composition, inflammation, oxidative stress, gut microbiota and glycemic response.  
Low glycinin soymilk (LGS) consumption caused less body fat accumulation than 
conventional soymilk (S) and bovine milk (M) (P = 0.017) after three months of consumption 
however no biological relevant changes among treatments were observed in total lean 
composition (P = 0.201), bone mass density (P = 0.060), BMD-t-scores (P = 0.094), waist-hip 
ratio (P = 0.454), BMI (P = 0.721) or weight (P = 0.836). 
Relative differences from baseline in serum oxidized LDL decreased after LGS 
consumption (-61 ± 7.1%) in comparison to S (-36 ± 4.3%) and M (-12 ± 5.4%), (p = 0.001). 
Serum antioxidant capacity increased in LGS (18% ± 3.5) and S (28%±4.6) in comparison to M 
(-40 ± 9.9%), (p < 0.0001). Plasma adiponectin increased after three months of consumption of 
LGS (14.9 ± 5.3%) compared with S (3.8 ± 4.5%) and M (-7.8 ± 4.4%), (p = 0.034). The results 
suggest that LGS consumption can significantly improve the oxidative stress status. Considering 
that oxidized LDL is a biomarker of diabetes and other metabolic syndrome related conditions, 
serum antioxidant capacity and high level of adiponectin have been prove to decrease oxidative 
stress, under the condition of this study we can conclude that the consumption of soymilk with 
high content of β-conglycinin reduce oxidative stress in overweight men.  
Plasma interleukin-6 after the consumption of LGS (-22 ± 9%) and S (-26 ± 5%) were 
significantly reduced in comparison to M (10.29 ± 12), (p = 0.044). Plasma CRP and TNFα did 
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not present differences after three months among treatments. The clear reduction in plasma 
interleukin-6 observed, confirms the hypothesis that soymilk has potential to protect against 
inflammation. Other biomarkers like plasma leptin (P = 0.655), plasma CRP (P = 0.959), plasma 
fatty acid synthase FAS (P = 0.976), plasma tumor necrosis alpha TNFα (P = 0.610), serum total 
cholesterol (P = 0.320) and serum triglycerides (P =0.947) did not have an effect under the 
conditions of this study with the treatments. 
Moderate physical activity (P=0.210) and strenuous physical activity (P=0.490) did not 
change or influence other data. Changes in dietary intake of energy, total protein, fat, 
carbohydrates, dietary fiber, Ca, Fe, P, K, caffeine, vitamins D, B-12, K, and E were not 
influenced by treatments during the study (P >0.05). However, sodium (P =0.019) and vitamin C 
(P =0.0002) intakes were reduced throughout time with the consumption of LGS. 
 Based on q-PCR, gut microbiota density increased with consumption of all treatments (P 
< 0.05). Changes in universal microbiota (P = 0.266), Bacteroides (P =0.266), Bifidobacteria (P 
= 0.068) and Lactobacillus (P = 0.063) were not different among treatments; however, the effect 
of the treatments were nearly significant in Bifidobacteria abundance showing a decrease with 
the soymilk treatments. After a high throughput analysis of fecal samples, our results shown an 
increase in Bacteroidetes relative abundance with consumption of LGS (30±11%, p<0.0001) and 
S groups (29 ± 10%, p=0.0001).  The relative abundance of Firmicutes decreased for both the 
LGS (-4±2%, p<0.0001) and S groups (-6 ± 2%, p<0.0001) yet increased for the M group 
(3±3%, p=<0.0001).  Based in the clear evidence of Firmicutes – Bacteroidetes composition in 
obese gut microbiota, we considere a positive that consumption of LGS and S may have a 
positive impact on Bacteroidetes and Firmicutes relative abundance and may help to reverse 
metabolic disorders in overweight men.  
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All treatments used in the present human study are considered low glycemic index. 
Postprandial glycemic responses were not affected with the consumption of LGS, S or M (p = 
0.338) allowing us to conclude that beverages with different protein profiles with same glycemic 
index does not have different glucose response and specifically β-conglycinin does not affect 
blood glucose concentration in overweight men. A graphic summary of the results generated in 
this study is presented in Figure 42. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42. Summary of effect of LGS consumption in overweight men. 
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VIII. CONCLUSIONS 
 
 Low glycinin soymilk ameliorates a modest but significant amount of body fat accumulation 
in comparison to conventional soymilk and bovine milk in overweight men. 
 
 Low glycinin soymilk decreases serum oxidized LDL more than conventional soymilk and 
bovine milk in overweight men.  
 
 Low glycinin soymilk reduces plasma interleukin-6 and improves serum antioxidant status 
compared to bovine milk in overweight men.  
 
 The consumption of low glycinin soymilk may be useful to prevent body fat accumulation 
and reverse oxidative stress.  
 
 Three months of low glycinin soymilk consumption increased plasma adiponectin in 
overweight men. 
 
 The consumption of low glycinin soymilk for three months may not have any physiologically 
important effect on lean composition or bone mineral density in overweight men. 
 
 Nutrients intake was maintained with low glicinin soymilk consumption, however reduction 
of vitamin C and sodium intake was observed. 
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 Under the conditions of this study microbial density increased in the same proportion with 
soymilk and bovine milk consumption. 
 
 Gut Bifidobacteria abundance decreased with soymilk consumption following the normal 
tendency in overweight and obese individuals; however the total Actinobacteria phylum 
abundance increased.  
 
 Low glycinin soymilk and conventional soymilk had a positive decrease in Firmicutes 
abundance and increase in Bacteroidetes. 
 
 Our results suggested that the high content of β-conglycinin in low glycinin soymilk did not 
have an effect in postprandial blood glucose response in overweight men. 
 
 The high content of β-conglycinin in low glycinin soymilk contain bioactive peptides that 
may be a useful therapeutic strategy to include in meals designed to reduce inflammation, 
oxidative stress and to alters gut microbiota composition with potential anti-obesity effect in 
overweight men. 
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IX. FUTURE STUDIES 
 
i. Based on the body composition results, and other studies in the literature, a longer period 
of treatment may have allowed more changes in body composition. DXA scans may be 
performed at baseline, 3 months and 6 months of consumption. 
ii. An increment in sample size (63/treatment), to compare among treatments, will increase 
the power analysis for parameters such as plasma C-reactive protein, serum leptin, 
plasma tumor necrosis factor α, serum total cholesterol and plasma fatty acid synthase. 
Based on power analysis, more than 1000 subjects per treatment may be required to see 
changes in serum triglycerides among overweight men. For future studies, the subject 
eligibility criteria should be narrowed to avoid influences of age and BMI as observed in 
this study with the serum oxidized-LDL changes. Subjects with a BMI between 25 - 29 
and age of 18 - 35 years may reduce the variability.  
iii. To detect differences among treatments in Bifidobacteria, Firmicutes, Lactobacillus and 
Proteobacteria, the sample size should increase to 56 subjects per treatment to have a 
power analysis of 80%. For Bacteroides analysis more than 4000 subject per treatment 
will be required to have a sample power of 80%. 
iv. More detailed restrictions on carbohydrate intake one day before blood glucose 
assessment will standardize the conditions of the subjects in future glycemic response 
studies. 
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APPENDIX A 
 
 
 
 
 
 
 
 
Flier used in the recruitment process 
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APPENDIX B 
Health questionnaire 
"Soymilk protein profile modulates human adipogenesis through changes in gut microbiota." 
 
Complete name: _____________________________________ Age: ________________ 
 
Are you:  American        or     International   → Country: ______________________ 
 
Email:___________________________________________Phone: _________________ 
 
Local Address:___________________________________________________________ 
 
INSTRUCION: Mark or give color to the word YES or NO. Change the name of the file with your name and send 
this document to dinafer@illinois.edu 
 
1. Are you allergic to soy products?          Yes     No 
 
2. Are you lactose intolerant?             Yes     No 
 
3. Do you weigh more than 300 pounds?             Yes     No 
 
4. Are you an athlete?            Yes     No 
    
5. Do you suffer from any physical or mental disease,                       Yes     No 
or have you ever had a major surgery? 
 
6. Do you take antibiotics or dietary supplements?        Yes     No 
 
7. Do you smoke?              Yes     No 
 
8. Are you a vegetarian?           Yes     No 
 
9. Do you suffer from any chronic disease?            Yes     No 
(i.e., chronic constipation, diarrhea, ulcerative colitis, irritable bowel syndrome,  
diverticulosis, stomach or duodenal ulcers, hepatitis, HIV, cancer, etc.)   
     
10. Are you overweight (BMI 25-30).                     Yes     No 
Your weight is ______(Pounds) and your height is _____(feet)    
  
11. Are you willing to avoid the consumption of any soy food                    Yes     No 
products during the week before the study? 
 
12. Are you willing to consume two (250 ml) Tetra-Pak containers of       Yes     No 
soymilk or cow milk every day during three months?  
 
13. Are you willing to avoid the intake of additional soymilk or                 Yes     No   
cow milk during the study? 
 
14. Are you willing to give blood and feces specimens?         Yes     No 
 
15. Are you willing to let us scan you body with DXA machine                    Yes     No 
and to measure your weight, height and circumferences every month? 
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16. Are you willing to avoid any food product with pre-probiotics?           Yes     No 
 
17. Are you willing to don’t change your normal physical activity during the next three months?    
                                Yes     No 
 
18. Are you student?                            Yes     No 
If yes: 
Department: __________________________________________________ 
Are you graduate or undergrad student? ____________________________ 
 
19. If you are international student; do you have a 50% of appointment?         
       Yes     No 
 
20. If you are International; are you willing to provide copies of personal documents like; (Visa, passport ID, I-20 
or DS2019, entry stamps, I-94, social security, I-card) this documents are required to receive a payment of $500.                           
  Yes     No 
 
21. Are you employee of the university of Illinois                                    Yes     No 
 Department: ____________________________________________ 
 
22. Are you available to attend meetings the following dates?  
First meeting for samples collection: September 21, 22 or 23th        Yes     No 
Second meeting for samples collection: October 19, 20 or 21th       Yes     No 
Third meeting for samples collection: November 16, 17 or 18
th
        Yes     No 
Last meeting for samples collection: December 14, 15 or 16
th
        Yes     No 
 
Comments about the dates: 
_____________________________________________________________________________________________
_________________________________________________ 
 
 
 
Thanks for your participation in this study 
 
 
 
 
 
 
 
 
107 
 
APPENDIX C 
DOCUMENTS USED FOR DIETARY INSTRUCTIONS 
************************************************************* 
List of prebiotic and probiotic products to avoid during the study 
 
 
Probiotic and prebiotic supplements 
 
All food products with level highlighting phrases like active bacteria, live cultures, active 
culture, prebiotic and prebiotic. 
 
Yogurts with pro and pebiotics 
o Dannon 
o Yoplait plus 
o Stonyfield Farm 
o Whole Soy & Co. 
o Turtle Mountain 
 
Milk, cereals and breakfast bars with probiotic yogurt 
powder or active cultures 
 
Smoothies 
o Healthy Dairy 
o Stonyfield Farm 
o Satiety Smoothies 
o Dannon 
 
Probiotic Frozen Yogurt 
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Foods to Avoid during one - week before the study 
 Any food containing the word soy, for example, soy milk, soy flour, soy yogurt… etc 
 Meat alternatives  
 Prebiotic and probiotic yogurt, kefir, fermented products, pre and probiotics supplements 
 Veggie/Garden Burgers 
 Soy Fiber (Okara, Soy Bran, Soy Isolate Fiber)  
 Kashi products 
 Yuba (Yuba is made by lifting and drying the thin layer formed on the surface of cooling hot soymilk. It 
has high protein content and is commonly sold fresh, half-dried and dried) 
 Dry blended beverages 
 Food bars 
 Protein bars 
 Dijon Style Mayonnaise or mustard 
 Chai 
 Keto Mix (mix for pancakes and muffins)  
 Lean Shakes 
 Canned chicken broth 
 Fast Food (example, McDonald’s, Wendy’s, Burger King) 
 Vegetable broth, gum, and starch 
 Bouillon cubes (beef, chicken, vegetable, etc.) 
 Smoothies 
 Textured vegetable protein: Textured soy protein (TSP) usually refers to products made from textured soy 
flour, although the term can also be applied to textured soy protein concentrates and spun soy fiber. 
 Hydrolyzed vegetarian protein (HVP): HVP is a flavor enhancer that can be used in soups, broths, sauces, 
gravies, flavoring and spice blends, canned and frozen vegetables, meats and poultry 
 Lecithin: Lecithin is used in food manufacturing as an emulsifier in products high in fats and oils. It also 
promotes stabilization, antioxidation, crystallization and spattering control. 
 Miso: Miso is a rich, salty condiment that characterizes the essence of Japanese cooking. The Japanese 
make miso soup and use it to flavor a variety of foods. Miso is made from soybeans and a grain such as 
rice, plus salt and a mold culture, and then aged in cedar vats for one to three years 
 Natto: Natto is made of fermented, cooked whole soybeans. 
 Soy Sauce (Tamari, Shoyu, Teriyaki) 
 Tempeh: Is a traditional Indonesian food, is a chunky, tender soybean cake. Whole soybeans, sometimes 
mixed with another grain such as rice or millet, are fermented into a rich cake of soybeans with a smoky or 
nutty flavor. Tempeh can be marinated and grilled and added to soups, casseroles, or chili. 
 Tofu: A type of cheese made out of soybeans. 
 
Some other things to keep in mindSome salad dressings, mayonnaise, sauces, or gravies may 
contain soy products 
 Margarine and butter substitutes, may contain soy products 
 Soy products may be used in some commercial ice creams and other frozen desserts 
 Baked goods, such as cakes or cookies which contain soy flour 
 Soy is used in many canned soups, commercial entrees, and combination foods 
 Some commercially prepared meats use soy as a meat extender 
 Pork link sausage, deli/luncheon meats may be made with soy 
 
 
109 
 
 
Food Tracker-Soymilk project
Panelist code: _________
INSTRUCTIONS:
3) Please fill up this table one week before the DXA appointment.
4) To have a better idea about portions visit: http://www.webmd.com/diet/healthtool-portion-size-plate
Note: In column B = Breakfast (B), Lunch (L), Dinner (D), Extras (E)
Day B / L / D / E Food
Homemade / 
Takeout
Brand/     
Restaurant Units Amount
2) If the food is homemade please specify general details of preparation and ingredients. If it is not 
homemade name a brand or give details of ingredients, or name a restaurant.  
1) Please record all the food you ate during five days (include at least a Saturday and a Sunday). 
Please provide most details as possible. Include alcoholic and non alcoholic beverages, candies, 
snacks, etc
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APPENDIX D  
 
 
 
 
 
 
 
 
 
 
 
 
 
Compliance assessment (returned codes) 
 
 
 
 
 
 
 
 
Panelists 1ST MONTH 2ND MONTH 
3RD 
MONTH 
  Returned  Codes 
Returned  
Codes 
Returned  
Codes 
Conventional 
soymilk 52 52 55 
% 92 93 98 
Low glycinin 
soymilk 50 53 52 
% 90 94 92 
Bovine milk 
 54 54 55 
% 96 96 98 
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APPENDIX E 
 
 
 
 
 
 
Body weight changes over time, among treatments, was observed (p = 0.932), means ± 
SEM. 
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APPENDIX F 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Minerals intake during the three months of treatment consumption 
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Vitamins intake during the three months of treatment consumption 
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APPENDIX G 
 
 
 
 
 
 
* Data are means ± SD (p > 0.05).  Total isoflavones concentration in bovine’s milk was < 1 ppm 
 
Isoflavones (If) concentration (ppm) in S and LGS.* 
 
 
*Differences in Thr, Ala, Gly, Ile, Leu, Tyr, Phe, Cys and Met between S and GLS were < 1 mg/g. Means ± SD. 
 
Amino acids concentration (mg/g) in S and LGS.* 
SDS-PAGE of soymilk powders 
Type 
SDS-PAGE 
Gel Lane 
LOX 
2&3 
% 
LOX 
1 % 
Alph
a' BC 
% 
Alpha BC 
% 
alpha / 
alpha' 
Beta 
BC % 
Total 
BC % 
A3 
gly 
% 
A1,2,4 
Gly % 
Basic 
Gly % 
Total 
Glycini
n % 
KTI 
% 
Control 
E-9204 
123-05 3.8 1.6 8.7 12.1 1.4 5.4 26.2 3.4 16.5 18.8 38.6 3.6 
HBC 
E-9204 
123-03 4.1 1.7 18.5 22.3 1.2 7.1 48.0 0.0 2.4 3.5 5.9 4.8 
HBC 
E-9204 
123-04 4.1 1.6 17.7 22.7 1.3 7.5 47.9 0.0 2.7 3.6 6.3 4.5 
HBC 
E-9204 
123-02 4.3 1.7 19.0 23.5 1.2 7.2 49.6 0.0 2.4 3.5 5.8 4.5 
HBC 
E-9204 
123-07 4.0 1.7 17.9 22.5 1.3 8.2 48.6 0.0 2.8 3.5 6.3 4.4 
HBC 
E-9204 
123-06 4.1 1.7 17.8 22.8 1.3 7.9 48.5 0.0 2.8 3.6 6.4 4.5 
HBC 
E-9204 
123-01 4.4 1.7 18.2 23.6 1.3 7.1 49.0 0.0 2.4 3.6 6.0 4.8 
Control 
E-9204 
123-14 4.0 1.6 9.0 12.2 1.4 5.6 26.8 3.5 16.5 18.8 38.8 3.2 
HBC 
E-9204 
123-12 4.0 1.5 18.3 23.8 1.3 7.6 49.7 0.0 2.4 3.3 5.7 4.3 
HBC 
E-9204 
123-13 4.2 1.6 18.6 24.3 1.3 7.7 50.5 0.0 2.7 3.1 5.8 4.1 
HBC 
E-9204 
123-11 4.0 1.6 18.3 24.2 1.3 7.8 50.4 0.0 2.5 3.2 5.6 3.5 
HBC 
E-9204 
123-16 4.3 1.7 18.6 23.9 1.3 7.9 50.3 0.0 2.7 3.1 5.8 3.4 
HBC 
E-9204 
123-15 4.3 1.7 18.6 24.2 1.3 7.8 50.5 0.0 2.9 3.1 6.0 3.4 
HBC 
E-9204 
123-10 4.1 1.6 18.7 23.9 1.3 7.7 50.3 0.0 2.6 3.3 5.9 3.9 
Control = Conventional soymilk, HBC = Low glycinin soymilk 
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APPENDIX H 
 
 
 
 
 
 
 
 
Individual subject analysis of changes in universal microbiota per treatment  
 
 
 
 
 
 
 
 
 
 
Individual subject analysis of changes in Bacteroides per treatment  
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Individual subject analysis of changes in Bifidobacteria per treatment  
 
 
 
 
 
 
 
 
 
Individual subject analysis of changes in Lactobacillus per treatment  
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APPENDIX I 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Postprandial blood glucose response after LGS, S and M consumption 
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APPENDIX J 
 
Incremental are under the curve of the postprandial glycemic response per treatment 
 
 
 
 
 
 
 
 
 
 
Exploratory analysis of incremental areas under the curve postprandial glycemic response 
per treatment per BMI 
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APPENDIX K 
Research poster presentation – Experimental Biology, Anaheim California 2010. 
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Research poster presentation – Institute of food technologist IFT, Chicago 2010. 
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Research poster presentation – Experimental Biology, Washington DC 2011.
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APPENDIX L 
 
Parameter Sample 
Power 
# of subjects 
per treatment 
for 80% 
power 
# of subjects 
per 
treatment for 
90% power 
# of subjects 
per treatment 
for 99% 
power 
Plasma C-reactive 
protein 
32% 47 61 113 
Plasma leptin 
 
29% 63 83 155 
Plasma TNFα 
 
45% 39 51 95 
Serum cholesterol 
 
45% 39 51 95 
Serum 
Triglycerides 
9% 348 456 857 
Plasma FAS 
 
30% 62 82 147 
Universal 
microbiota 
43% 45 59 109 
Bacteroides 
 
5% 4728 6209 11681 
Bifidobacteria 
 
45% 46 59 110 
Firmucutes 
 
37% 56 74 137 
Lactobacillus 
 
60% 33 42 78 
Proteobacteria 
 
39% 53 69 128 
Actinobacteria 
 
19% 121 159 297 
*Based on Sample Power analysis performed in SPSS for non-significant parameters.  
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APPENDIX M 
Sub RMR 
Baseline Month 1 Month 2 Month 3 
Energy 
intake 
Difference 
Adiponectin 
Kcal/Day Kcal/Day Kcal/Day Kcal/Day Average RD % 
F6-01 1981.1 2697.3 2683.0 1137.4 . 2172.6 191.5 31.1 
F6-02 1714.9 1317.0 2288.4 1958.1 1703.5 1816.7 101.9 29.2 
F6-03 1934.8 1949.6 1896.9 . 1918.8 1921.7 -13.1 -8.1 
F6-04 2140.8 2032.1 2196.6 2052.3 2324.5 2151.4 10.5 16.2 
F6-05 2198.9 3385.1 1986.3 2304.8 2400.6 2519.2 320.3 -11.6 
F6-06 1986.3 3081.0 2913.5 2831.0 2675.6 2875.3 889.0 -7.4 
F6-07 1916.5 3197.9 . 2350.7 3279.3 2942.6 1026.1 -5.6 
F6-08 2166.9 2000.4 7203.5 2146.9 4043.9 3848.7 1681.7 38.9 
F6-09 1761.0 1629.2 2111.1 2691.3 2277.6 2177.3 416.3 20.3 
F6-10 1699.0 1607.2 2127.1 1627.0 1642.7 1751.0 52.0 -23.3 
F6-11 1838.3 1639.1 904.9 2025.9 1953.6 1630.9 -207.5 10.6 
F6-12 2131.4 1589.7 3781.0 2304.1 3728.1 2850.7 719.3 21.2 
F6-13 2253.4 2772.9 2383.1 1566.6 2244.9 2241.9 -11.5 -11.2 
F6-15 2029.0 8216.1 3077.4 2262.6 2670.8 4056.7 2027.7 10.6 
F6-16 1892.2 3232.5 2172.2 2636.2 2728.3 2692.3 800.1 0.5 
G6-01 2183.9 1623.6 4153.2 3116.1 1880.7 2693.4 509.5 -8.9 
G6-02 1841.2 1557.1 1830.7 810.1 1202.6 1350.1 -491.1 14.9 
G6-03 2009.8 4331.4 3151.0 2781.1 2619.2 3220.7 1210.8 3.4 
G6-04 1941.9 4063.1 2426.2 3817.1 3219.4 3381.4 1439.6 17.4 
G6-06 1927.9 1748.1 2309.5 1924.5 2725.2 2176.8 248.9 6.1 
G6-07 1677.9 2224.8 1551.2 1170.1 1747.3 1673.3 -4.6 23.4 
G6-10 1927.4 3664.9 2984.6 3097.6 2919.3 3166.6 1239.2 -15.9 
G6-12 2033.8 3065.4 3333.7 2873.8 3601.0 3218.5 1184.7 5.1 
G6-13 1875.6 2206.6 1305.4 1049.8 1565.4 1531.8 -343.8 43.0 
G6-14 2134.3 4380.1 2218.8 2186.8 2472.5 2814.5 680.2 48.9 
H6-01 1683.2 2280.2 2491.2 2495.3 2258.5 2381.3 698.1 17.6 
H6-02 2276.5 904.0 718.5 1006.4 870.1 874.7 -1401.8 16.2 
H6-03 1939.4 2559.9 2302.3 2211.8 2103.8 2294.4 355.0 -5.3 
H6-04 1795.6 1987.2 2376.3 1901.1 1192.1 1864.1 68.5 2.0 
H6-05 2208.4 2167.7 2379.8 2858.3 2221.8 2406.9 198.5 3.2 
H6-07 1679.2 1518.3 531.5 1393.0 917.9 1090.2 -589.0 5.2 
H6-08 1914.4 2706.8 3160.9 3602.8 3450.0 3230.1 1315.7 12.5 
H6-09 1910.6 1488.7 1742.4 1958.2 1432.8 1655.5 -255.1 9.4 
H6-11 2108.7 2109.3 1667.6 2247.2 1995.3 2004.8 -103.9 1.5 
H6-12 1913.7 2180.5 2814.0 2719.2 2401.5 2528.8 615.1 -33.9 
H6-13 1867.7 845.3 1473.0 2026.6 1593.6 1484.6 -383.1 -11.8 
H6-14 1724.3 2408.1 2620.2 2554.1 2264.8 2461.8 737.5 . 
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ESTIMATED ENERGY INTAKE PER SUBJECT DURING THE STUDY 
 
* BMR (basal metabolic rate) was calculated with the Mifflin-St Jeor formula (BMR = 9.99 X 
weight + 6.25 X height – 4.92 X age + 5). According to the energy consumption declared by 
participants, some of the participants did not met the energy requirement, however, after an 
analysis of energy intake throughout the time, no significant differences were found among 
groups (LGS, S and M) every month  and not significant changes were detected (P = 0.130) 
throughout the three months of consumption. Also a mixed model analysis, showed that energy 
intake did not influenced changes in plasma adiponectin (P = 0.642). 
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